EP0869779A1 - UTILISATION D'INHIBITEURS DE L'ECHANGEUR CELLULAIRE Na?+ /H?+ (NHE) POUR PREPARER UN MEDICAMENT STIMULANT LA RESPIRATION - Google Patents

UTILISATION D'INHIBITEURS DE L'ECHANGEUR CELLULAIRE Na?+ /H?+ (NHE) POUR PREPARER UN MEDICAMENT STIMULANT LA RESPIRATION

Info

Publication number
EP0869779A1
EP0869779A1 EP96943956A EP96943956A EP0869779A1 EP 0869779 A1 EP0869779 A1 EP 0869779A1 EP 96943956 A EP96943956 A EP 96943956A EP 96943956 A EP96943956 A EP 96943956A EP 0869779 A1 EP0869779 A1 EP 0869779A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
hydrogen
group
independently
zero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96943956A
Other languages
German (de)
English (en)
Inventor
Klaus Wirth
Wolfgang Scholz
Hans-Willi Jansen
Hans Jochen Lang
Joachim Brendel
Heinz-Werner Kleemann
Jan-Robert Schwark
Andreas Weichert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of EP0869779A1 publication Critical patent/EP0869779A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60L—PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L50/00—Electric propulsion with power supplied within the vehicle
    • B60L50/50—Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells
    • B60L50/60—Electric propulsion with power supplied within the vehicle using propulsion power supplied by batteries or fuel cells using power supplied by batteries
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60L—PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L7/00—Electrodynamic brake systems for vehicles in general
    • B60L7/10—Dynamic electric regenerative braking
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60L—PROPULSION OF ELECTRICALLY-PROPELLED VEHICLES; SUPPLYING ELECTRIC POWER FOR AUXILIARY EQUIPMENT OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRODYNAMIC BRAKE SYSTEMS FOR VEHICLES IN GENERAL; MAGNETIC SUSPENSION OR LEVITATION FOR VEHICLES; MONITORING OPERATING VARIABLES OF ELECTRICALLY-PROPELLED VEHICLES; ELECTRIC SAFETY DEVICES FOR ELECTRICALLY-PROPELLED VEHICLES
    • B60L7/00—Electrodynamic brake systems for vehicles in general
    • B60L7/10—Dynamic electric regenerative braking
    • B60L7/16—Dynamic electric regenerative braking for vehicles comprising converters between the power source and the motor
    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01C—CONSTRUCTION OF, OR SURFACES FOR, ROADS, SPORTS GROUNDS, OR THE LIKE; MACHINES OR AUXILIARY TOOLS FOR CONSTRUCTION OR REPAIR
    • E01C19/00—Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving
    • E01C19/22—Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving for consolidating or finishing laid-down unset materials
    • E01C19/23—Rollers therefor; Such rollers usable also for compacting soil
    • E01C19/26—Rollers therefor; Such rollers usable also for compacting soil self-propelled or fitted to road vehicles
    • E—FIXED CONSTRUCTIONS
    • E01—CONSTRUCTION OF ROADS, RAILWAYS, OR BRIDGES
    • E01C—CONSTRUCTION OF, OR SURFACES FOR, ROADS, SPORTS GROUNDS, OR THE LIKE; MACHINES OR AUXILIARY TOOLS FOR CONSTRUCTION OR REPAIR
    • E01C19/00—Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving
    • E01C19/22—Machines, tools or auxiliary devices for preparing or distributing paving materials, for working the placed materials, or for forming, consolidating, or finishing the paving for consolidating or finishing laid-down unset materials
    • E01C19/23—Rollers therefor; Such rollers usable also for compacting soil
    • E01C19/28—Vibrated rollers or rollers subjected to impacts, e.g. hammering blows

Definitions

  • the invention relates to the use of NHE inhibitors for the manufacture of a medicament for respiratory stimulation
  • NHE inhibitors are guanidine derivatives, preferably acylguanidines, among others as described in the following publications and patent publications: Edward J. Cragoe, Jr., "DIURETICS, Chemistry, Pharmacology and Medicine” , J. WILEY & Sons (1983), 303-341, also for compounds of the following formulas:
  • R (9) H or methyl; or R (7) and R (8) together with the nitrogen atom to which they are attached, a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system; R (3), R (4) and R (5) independently of one another H or (C r C 2 ) alkyl, or R (3) and R (4) together form a (C 2 -C 4 ) alkylene chain; or R (4) and R (5) together form a (C 4 -C 7 ) alkylene chain; and their pharmaceutically acceptable salts; (HOE 92 / F 34 - US 5 373 924) b) Benzoylguanidines of the formula I
  • R (1) R (4) -SO m or R (5) R (6) N-SO 2 -; m zero, 1 or 2; R (4) and R (5)
  • R (7) C 5 -C 7 cycloalkyl or phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (8) R (9); R (8) and R (9)
  • R (10) H, C r C 6 alkyl, C 5 -C 7 cycloalkyl, cyclohexylmethyl, cyclopentylmethyl or -C n H 2n -R (12); n zero, 1, 2, 3 or 4;
  • R (9); R (8) and R (9) are H or C r C 4 alkyl
  • R (11) is hydrogen or C r C 3 alkyl
  • R (10) and R (11) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by O, S, NH, N-CH 3 or N-benzyl
  • R (3) is defined as R (1), or C r C 6 alkyl, nitro, cyano, trifluoromethyl, F, Cl, Br, J or -XR (10); XO, S or NR (11);
  • R (10) is H, C r C 6 alkyl, C 5 -C 7 cycloalkyl, cyclohexylmethyl, cyclopentylmethyl or -C n H 2n -R (12); n zero to 4; R (12) phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (8) R (9); R (8) and R (9)
  • R (6) H, C r Cg-alkyl, C 5 -C 7 cycloalkyl, cyclohexylmethyl, cyclopentylmethyl, - (CH 2 ) m C p F 2p + 1 or -C n H 2n -R (8); m zero or 1; P 1-3; n zero to 4;
  • R (8) phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of the groups F, Cl, CF 3 , methyl, methoxy and NR (9) R (10); R (9) and R (10)
  • R (7) H or C r C 4 alkyl; R (7) H or C r C 3 alkyl; or R (6) and R (7) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by an O, S, NH, N-CH 3 or N-benzyl; R (3) H or -XR (6);
  • YO or NR (7) where Y is bonded to the phenyl radical of the formula I, ZC or SO; R (6) H, C 1 -C 6 alkyl, C 5 -C 7 cycloalkyl, cyclohexylmethyl, cyclopentylmethyl, - (CH 2 ) m C p F 2p + 1 or -C n H 2n -R (8); m zero or 1; P 1-3; n zero to 4; R (8) phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (9) R (10); R (9) and R (10)
  • R (12) and R (13) are defined as R (6) and R (7); or one of the two radicals R (2) or R (4) defines hydrogen or as R (1); R (5) H, methyl, F, Cl or methoxy, and their pharmaceutically acceptable salts.
  • R 92 / F 036 - US 5 364 868) d Benzoylguanidines of the formula I.
  • R (1) or R (2) is an amino group -NR (3) R (4);
  • R (3) and R (4), identical or different, are H, C r C 6 alkyl or C 3 -C 7 cycloalkyl; or
  • Oxygen, S or NR (5) can be replaced;
  • R (5) H or lower alkyl; the other substituent R (1) or R (2)
  • R (1) R (4) -SO m or R (5) R (6) N-SO 2 -; m zero, 1 or 2; R (4) and R (5)
  • R (7) C 5 -C 7 cycloalkyl or phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (8) R (9); R (8) and R (9)
  • R (6) H or C r C 4 alkyl; or R (5) and R (6) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by an O, S, NH, N-CH 3 or N-benzyl;
  • R (12) (C 3 -C ⁇ ) cycloalkyl;
  • R (13) is hydrogen or methyl, or
  • R (4) and R (5) together form a straight-chain or branched C 4 -C 7 chain, where the chain can additionally be interrupted by O, S or NR (6), R (6) H or methyl; or R (4) and R (5) together with the nitrogen atom to which they are attached, a dihydroindole, tetrahydroquinoline or tetrahydroisoquinoline system; n zero, 1 or 2; and their pharmaceutically acceptable salts. (92 / F 304 - US 5416 094) g) isoquinolines of the formula I.
  • R (1) hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or heteroaryl ring; the rings being unsubstituted or substituted with 1-3 groups selected from the group consisting of halogen, Nitro, amino, mono (lower alkyl) amino, di (lower alkyl) amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxy, trifluoromethyl, R (2) hydrogen, halogen, alkyl, or aryl; which is unsubstituted or substituted with 1-3 groups selected from the group consisting of halogen, nitro, amino, mono (lower alkyl) amino, di (lower alkyl) amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxy,
  • X (2), X (3) and X (4) independently of one another hydrogen, halogen, nitro, amino, alkyl, sulfonamide, mono (lower alk ⁇ l) amino, di (lower alkyl) amino, lower alkyl, benzyloxy, hydroxy;
  • X (1) hydrogen, oxygen, sulfur or NR (7);
  • R (7) is hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or heteroaryl ring; which rings are unsubstituted or substituted with 1-3 groups selected from the group consisting of halogen, nitro, amino, mono (lower alkyl) amino, di (lower alkyl) amino, lower alkyl, lower alkoxy, benzyloxy, phenoxy, hydroxy and trifluoromethyl; in which substituents each alkyl chain or alkenyl chain can be interrupted by oxygen, sulfur or NR (8); R (8) hydrogen, alkyl, cycloalkyl, arylalkyl, alkenyl, substituted aminoalkyl or an aryl or heteroaryl ring, which rings are unsubstituted or substituted with 1-3 groups selected from the group consisting of halogen, nitro, amino, mono (lower alkyl) amino, Di (lower alk ⁇ l)
  • R (7) (C 3 -C 7 ) cycloalkyl or phenyl, which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (8) R ( 9); ° R (8) and R (9)
  • R (6) H or (C r C 4 ) alkyl; or R (5) and R (6) together 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; R (2) -SR (10), -OR (10), -NHRdO), -NR (10) R (1 1), -CHR (10) R (12), - [CR (12) Rd 3) OR (13 ')], - ⁇ C- [CH 2 -OR (13')] R (12) (R (13) ⁇ or - [CR (18) Rd 7)] p - (CO) - [CR (19) R (20)] q -R (14); RdO), R (11) the same or different
  • R (21) hydrogen, methyl, p, q, r the same or different
  • R (12) and R (13), identical or different, are hydrogen, (C 1 -C 6 -alkyl or together with the carbon atom carrying them a (C 3 -C 8 ) cycloalkyl, R (13 ') hydrogen or (C r C 4 ) alkyl;
  • R (14) H, (C r C 6 ) alkyl, (C 3 -C 8 ) cycloalkyl or -C a H 2a -R (15); a zero, 1, 2, 3 or 4;
  • X is oxygen, S or NR (16); R (16) H or (C r C 3 ) alkyl; or R (22) and R (16) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; R (22) is defined as R (14); and their pharmaceutically acceptable salts.
  • R (16) H or (C r C 3 ) alkyl; or R (22) and R (16) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; R (22) is defined as R (14); and their pharmaceutically acceptable salts.
  • HOE 92 / F 405 - EP 602 523, NZ 250437 i) Benzoylguanidines of the formula I
  • R (7) (C 3 -C 7 ) cycloalkyl or phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (8) R ⁇ 9); R (8) and R (9)
  • R (1 1) and R (12) independently of one another are defined as R (10) or hydrogen or (C r C 4 ) -alkyl; R (3) is defined as Rd), or (C r C 6 ) alkyl or -XR (13); X is oxygen, S, or NR (14); R (14) H or (C r C 3 ) alkyl; R (13) H, (C r C 6 ) alkyl, (C 3 -C 8 ) cycloalkyl or -C b H 2b -R (15); b zero, 1, 2, 3 or 4; or R (13) and R (14) together 4 or 5 methylene groups, of which CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; R (15) phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (8) R (9); R (8) and R (9)
  • R (5) is hydrogen or C (1. 6) alkyl; n zero, 1, 2, 3 or 4;
  • R (6) H or C ⁇ 1-4r alkyl; wherein a CH 2 group can be replaced by 1 S atom or a group NR (7);
  • R (7) hydrogen, methyl or ethyl
  • R (5) and R (6) together with the nitrogen atom form a 5-, 6- or 7-membered ring in which 1 C atom can be replaced by oxygen, S or NRdO); Rd O) H, C ( 1.3 ) alkyl or benzyl; and the other substituents R (1), R (2), R (3), R (4):
  • X is oxygen or NR (12); R (12) H or C (1.3) alkyl; R (11) is hydrogen, C (1. 6) alkyl, C (3. 8) cycloalkyl or phenyl which is unsubstituted or substituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, CH 3 , CH 3 -O- and NR (13) R (14); Rd 3), R (14)
  • X is oxygen, S or NR (6); R (4) and R (5) the same or different, H, (C 1 -C 8 ) alkyl, (C 3 -C 6 ) alkenyl or
  • n 0, 1, 2, 3 or 4;
  • Rd O phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (1 1) R (12); R (1 1) and R (12)
  • Substituents R (1), R (2) or R (3) represent a sufficiently lipophilic alkyl radical having 3 to 12 carbon atoms; or one of the substituents R (1), R ⁇ 2) or R (3)
  • R (4) (C 3 -C 12 ) cycloalkyl, phenyl, pyridyl, quinolyl or isoquinolyl, where the aromatic and heteroaromatic ring systems are unsubstituted or substituted with a substituent selected from the group consisting of F, Cl, CF 3 , methyl, Methoxy and NR (5) R ⁇ 6); R (5) and R (6)
  • -C ⁇ CR (5) or -C [R (6)] CR (5); R ⁇ 5) phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy, hydroxy, amino, methylamino and dimethylamino, (C 1 -C 9 ) heteroaryl which is unsubstituted or substituted like phenyl, or R (5) (C r C 6 ) alkyl which is unsubstituted or substituted by 1-3 OH; or
  • X is oxygen, S or NR (14); m zero, 1 or 2; o zero or 1; p zero, 1 or 2; q zero, 1, 2, 3, 4, 5 or 6; R ⁇ 5) and R (6)
  • R (8) (C 3 -C 7 ) cycloalkyl or phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (9) R ( 10); R (9) and R (10)
  • R (7) H or (C r C 4 ) alkyl; or R (6) and R (7) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl;
  • Y- Y is oxygen, -S- or -NR (12) -; R (1 1) and R (12)
  • R (3) defines as R (1), or (CT-CgJ-alkyl or -XR (13); X is oxygen, S or NRJ 14); R (14) H or (C r C 3 ) alkyl;
  • R (4) is hydrogen, -OR (16) or -NR (16) R (17); R (16) and R (17) independently are hydrogen or (C r C 3 ) alkyl; and their pharmaceutically acceptable salts; (HOE 93 / F 154 - EP-OS 628 543, NZ 260 681) p) Benzo ⁇ lguanidines of the formula I.
  • R (9) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (10) R (11); R (10) and R (1 1)
  • R (12) (C 3 -C 8 ) -C ⁇ cloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (13) R (14); R (13) and R (14)
  • R (19) and R (20) independently of one another are defined as R (18) or hydrogen, (C, - C 4 ) -alkyl or (C r C 4 ) -perfluoroalkyl; or
  • R (24) (C 3 -C 8 ) cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (27) R (28); R (27) and R (28)
  • R (29) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (30) R (31); R (30) and R (31)
  • R (36) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics not being substituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, Methoxy and NR (37) R (38); R (37) and R (38)
  • R (34) H, (C r C 4 ) alkyl or ⁇ C r C 4 ) perfualkyl;
  • R (34) H, (C r C 4 ) alkyl or (C r C 4 ) perfualkyl;
  • R (35) defines like R (33); or
  • R (33) and R (34) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; where A and N (#) are bound to the phenyl core of the benzoylguanidine base body; or
  • R (2) -SR (40), -OR ⁇ 40), -NHR (40), -NR (40) R (41), -CHR (40) R (42), -C [R (42) R (43) OH], -C ⁇ CR (45), -CR (46) CHR (45), - [CR ⁇ 47) R (48)] u - (CO) - [CR49) R (50)] v -R (44); R (40), R (41) the same or different - (CH 2 ) p - (CHOH) q - (CH 2 ) r - (CHOH) t -R (51) or - (CH 2 ) p -O- ( CH 2 -CH 2 O) q -R (51); R (51) is hydrogen or methyl; u 1, 2, 3 or 4; v zero, 1, 2, 3 or 4;
  • R (42) and R (43), identical or different, are hydrogen or (C, -C 6 ) -alkyl; or R (42) and R (43) together with the carbon atom carrying them form a (C 3 -C 8 ) cycloalkyl; R (44) H, (C r C 6 ) alkyl, (C 3 -C 8 ) cycloalkyl or -C ⁇ H 2 ⁇ -R (45); e zero, 1, 2, 3 or 4;
  • R (45) is phenyl, which is unsubstituted or substituted with 1-3 substituents from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (52) R (53) with
  • R (52) and R (53) are H or (C r C 4 ) alkyl, or R (45) (C r C 9 ) heteroaryl which is unsubstituted or substituted like phenyl; or R (45) (C r C 6 ) alk ⁇ l which is unsubstituted or substituted by 1-3 OH; R (46), R ⁇ 47), R (48), R ⁇ 49) and R (50) are hydrogen or methyl; or R (2) R (55) -NH-SO 2 -;
  • Y is oxygen, S or NR (58); R (56) and R (57), identical or different, are H, (C j -CgJ alkyl, (C 3 -C 6 ) alkenyl or -C f H 2f -R (59); f zero, 1, 2, 3 or 4;
  • R (59) (C 5 -C 7 ) cycloalkyl or phenyl, which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methoxy and (C r C 4 ) alkyl; or R ⁇ 56) and R (57) together 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl;
  • R (58) is defined as R (56) or amidine;
  • R (3), R (4) and R (5) are independently defined as R (1) or R (2); and their pharmaceutically acceptable salts; (HOE 93 / F 220 - EP-OS 640 593, NZ 264 1 17) q) benzoylguanidines of the formula I.
  • Rd hydrogen, F, Cl, Br, I, -NO 2 , -C ⁇ N, -X 0 - (CH 2 ) p - (CF 2 ) q -CF 3 , R (5) -SO m - R ( 6) -CO-, R (6) R (7) N-CO- or R (6) R (7) N-SO 2 -;
  • X is oxygen, -S- or NR (14); m zero, 1 or 2; o zero or 1; p zero, 1 or 2; q zero, 1, 2, 3, 4, 5 or 6;
  • R (8) (C 3 -C 7 ) cycloalkyl, phenyl which is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (9) R ( 10); R (9) and RdO)
  • R (7) is hydrogen or (C r C 4 ) alk ⁇ l; or R (6) and R (7) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl;
  • X is oxygen, -S- or NR (14); R (14) H or (C r C 3 ) alkyl;
  • R (4) is hydrogen, -OR (16), -NR (16) R (17) or C r F 2r + 1 ; R (16) and R (17) independently are hydrogen or (C 1 -C 3 ) alkyl; r 1, 2, 3 or 4; and their pharmaceutically acceptable salts; (HOE 93 / F 223 K - EP 639 573, NZ 264 130) r) Benzo-fused 5-ring heterocycles of the formula
  • Y is oxygen, S or NR (7);
  • R (9) H, methyl, ethyl,
  • W is oxygen or NR (10);
  • X is oxygen or S
  • R (6) hydrogen, (C r C 8 ) alkyl, (C r C 8 ) perfluoroalkyl, (C 3 -C 8 ) alkenyl or -C n H 2n -R (9); n zero, 1, 2, 3 or 4;
  • R (9) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (10) R (1 1); R (10) and R (11)
  • R (7) hydrogen, (C r C 8 ) alkyl, (C r C 8 ) perfluoroalkyl, (C 3 -C 8 ) -
  • R (12) (C 3 -C 8 ) -C ⁇ cloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (13) R (14); R (13) and R (14)
  • R (8) defines like R ⁇ 7); or R (7) and R (8) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; the remaining substituents R (2), R (3), R (4), R (5) or R (1), R (2), R (4), R (5) or R (1), R (2), R (3), R (5) independently of one another hydrogen, F, Cl, Br, I, -O ta (C, -C 8 ) alkyl,
  • R (21) (C 3 -C 8 ) cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents from the group F, Cl, CF 3 , methyl, methoxy or NR (22 ) R (23), R ⁇ 22) and R (23) hydrogen, (C r C 4 ) alkyl or (C r C 4 ) perfluoroalkyl; R (17) hydrogen, (C r C 8 ) alkyl, (C r C 8 ) perfluoroalkyl, (C 3 -C 8 ) alkenyl, - C r H 2r -R (24); r zero, 1, 2, 3 or 4;
  • R (24) (C 3 -C 8 ) cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (25) R (26); R (25) and R ⁇ 26)
  • R (A) and R (B) independently are hydrogen, F, Cl, Br, I, CN, OR (106), (C r C 8 ) alkyl, (C 3 - C 8 ) cycloalkyl, O 2k (CH 2 ) zl C zm F 22m + 1 , NR (107) R (108), phenyl or benzyl, the aromatics being unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl , Methoxy and NR (109) R (1 10); R (109) and R (1 10)
  • R (107) and R (108) independently of one another are defined as R (106), or R (107) and R (108) together have 4 or 5 methylene groups, one of which is a CH 2 group by oxygen, S, NH, N - CH 3 or N-benzyl can be replaced; or Xd) and X (2)
  • T2a and T2b independently of one another zero, 1 or 2; wherein the double bond can be (E) - or (Z) -configured; or
  • T3 zero, 1 or 2;
  • U, YY and Z independently of one another are C or N, where U, YY, Z can carry the following number of substituents:
  • R (1 15) and R (1 16) are independently defined as R (1 14); or
  • R (110c) and R (1 13a) independently are hydrogen, (C 1 -C 4 ) perfluoroalkyl or (C 1 -C 4 ) alkyl; or R (1 10b) and R (1 10c) and R (1 12a) and R (1 13a) together 4 or 5 methylene groups, one of which is a CH 2 group by oxygen, sulfur, NH, N-CH 3 or N -Benzyl can be replaced; or R (101), R (102), R (103), R (104), R (105) independently of one another (C ⁇ CgV-alkyl, -C za
  • R (101), R (102), R (103), R ⁇ 104), R (105) independently of one another -C C-R (193); R (193)
  • Phenyl which is unsubstituted or substituted with 1-3 substituents from the group consisting of F, Cl, CF 3 , methyl, methoxy or NR (194) R (195); R (194) and R (195)
  • R (101), R (102), R (103), R (104), R (105) independently of each other
  • R (101), R (102), R (103), R (104) and R (105) independently of one another R (146) X (1a) -; Xd a)
  • -C 2xa H 22xa -R (151); eg zero or 1; zdz 1, 2, 3, 4, 5, 6 or 7; zxa zero, 1, 2, 3 or 4;
  • R (168), R (170), R (154), R (155), the same or different, are hydrogen or ⁇ C r C 6 ) -alkyl, or R (169) and R (170) or R (154) and R (155) together with the carbon atom carrying them a (C 3 -C 8 ) cycloalkyl; R (163)
  • R (156), R (157) and R (173) are independently phenyl which is unsubstituted or substituted with 1-3 substituents from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (174) R (175 ); R (174) and R (175)
  • R (156), R (157) and R (173) independently (C ⁇ Cgl heteroaryl which is unsubstituted or substituted like phenyl;
  • R (158), R (159), R (160), R (161) and R (162) are hydrogen or methyl, or R (101), R (102), R ⁇ 103), R (104), R (105) independently of one another R (176) -NH-SO 2 -;
  • R (177) and R (178), identical or different, are hydrogen, (C -, - C 8 ) -alkyl, (C 3 -C 6 ) -alkenyl or -C zfa H 2zfa -R (180); zfa zero, 1, 2, 3 or 4; R (180)
  • R (177) and R (178) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, sulfur, NH, N-CH 3 or N-benzyl;
  • R (179) is defined as R (177) or the same as amidine, or R (101), R (102), R (103), R (104), R (105) independently of one another NR (184a) R (185), OR (184b), SR (184c) or
  • X is oxygen, S or NR (5); a zero or 1; b zero, 1 or 2; c zero, 1, 2 or 3;
  • R (5) H, (C r C 4 ) alkyl or -C d H 2d R (6); d zero, 1, 2, 3 or 4;
  • R (6) (C 3 -C 8 ) cycloalkyl, phenyl, biphenylyl or naphthyl, where the aromatics are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (7) R (8); R (7) and R (8) independently represent H or (C r C 4 ) alkyl; or R (1) -SRdO), -OR (10) or -CR (10) R (1 1) R (12);
  • RdO -C f H 2f - (C 3 -C 8 ) -cycloalkyl, - (CT-CgJ-heteroaryl or phenyl, where the aromatic systems are unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; f zero, 1 or 2;
  • R (11) and R (12) are independently defined as Rd O) or hydrogen or (C r C 4 ) alkyl; or
  • R ⁇ 13) and R (14) the same or different - (CH 2 ) 0 - (CHOH) h - (CH 2 ) r (CHOH) r R (17), R (17) hydrogen or methyl; - (CH 2 ) ⁇ -O- (CH 2 -CH 2 O) h -R (24), g, h, i the same or different zero, 1, 2, 3 or 4; j 1, 2, 3 or 4;
  • R (15) and R (16), identical or different, are hydrogen, (C
  • R (18) (C 3 -C 8 ) cycloalkyl; R (19), R (20), R (21), R (22) and R (23)
  • R (6) hydrogen, (C r C 8 ) alkyl, (C 3 -C 8 ) alkenyl, (C 3 -C 8 ) cycloalkyl, phenyl or benzyl, where the aromatics are not substituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (9) R (10); R (9) and Rd O)
  • R (7) and R (8) are independently defined as R (6);
  • R (B) is independently defined as R (A); X 1, 2 or 3;
  • R (1) hydrogen, (C 1 -C 8 ) alkyl, (C 3 -C 8 ) cycloalkyl, -O t (CH 2 ) d C e F 2 ⁇ + 1 , F, Cl,
  • R (2), R (3), R (4) and R (5) are independently defined as R (1); but under the condition that at least one of the substituents R (1), R (2), R (3), R (4), R (5), R (A) and R (B) has an -O t (CH 2 ) d C e F 2e + 1 or an O r (CH 2 ) a C b F 2b + 1 group, and their pharmaceutically acceptable salts; (HOE 94 / F 094 - EP-OS 676 395, NZ 270 894) x) heteroaroylguanidines of the formula I.
  • HA SO m 0 or NR (5); m zero, 1 or 2;
  • R (81) (CT -C 9 ) heteroary I which is linked via C or N and which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy , Hydroxy, amino, methylamino and dimethylamino; one of the two substituents R (1) and R ⁇ 2)
  • R (3) and R (4) independently of one another hydrogen, F, Cl, Br, I, -C ⁇ N, X- (CH 2 ) p - (C q - F 2q + 1 ), R (8) -SO bm , R (9) R (10) N-CO, R (1 1) -CO- or R (12) R (13) N-SO 2 -, where the perfluoroalkyl group is straight-chain or branched, X is oxygen, S or NR (14); R (14) H or ( ⁇ -C ⁇ alkyl; bm zero, 1 or 2; p zero, 1 or 2; q zero, 1, 2, 3, 4, 5 or 6;
  • R (8), R (9), R (1 1) and R (12) independently (C r C 8 ) alkyl, (C 3 -C 6 ) alkenyl, -C n H 2n -R (15) , CF 3 ; n zero, 1, 2, 3 or 4; R (15) (C 3 -C 7 ) cycloalkyl or phenyl; which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy or NR (16) R (17); R (16) and R (17)
  • RdO) and R (13) independently H or (C 1 -C 4 ) alkyl; or R (9) and Rd O) and R (12) and R (13) together 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl , or R (3) and R (4) independently of one another (C r C 8 ) -alkyl or -C a
  • R (18) (C 3 -C 8 ) cycloalkyl or phenyl; which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (19) R (20); R (19) and R (20)
  • R (3) and R (4) independently of one another (C r C 9 ) heteroaryl, which is linked via C or N and which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; or
  • Y is oxygen, -S- or -NR (22) -; h, ad, ah independently zero or 1; i, j, k, ae, af, ag, ao, ap and ak independently zero, 1, 2, 3, 4, but with h, i and k not simultaneously zero, ad, ae and ag not simultaneously zero and ah , ao and ak are not zero at the same time,
  • R (23), R (24) R (25) and R (22) independently are hydrogen or (C 1 -C 3 ) alkyl; or R (3) and R (4) independently of one another are hydrogen, F, Cl, Br, I, CN, (C 1 -C 8 ) -alkyl, (C ⁇
  • C 8 perfluoroalkyl, (C 3 -C 8 ) alkenyl or -C 8 H 2g R (26); g zero, 1, 2, 3 or 4;
  • R (26) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (27) R (28); R (27) and R (28)
  • R (29), R (30), R (31) and R (33) independently -CaH ⁇ -fC, -C 9 ) heteroaryl, which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F. , Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; a zero, 1 or 2;
  • R (32), R (34) and R (35) independently of one another are defined as R (29) or hydrogen, (C -, - C 4 ) -alkyl or (C r C 4 ) -perfluoroalkyl; or R (3) and R (4) independently of one another
  • R (96), R (97) and R (98) independently (C ⁇ Cgl-heteroaryl which is linked via C or N and which is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino, dimethylamino or benzyl; W oxygen, S or NR (36) -; R (36) H or (C r C 4 ) alkyl; or R (3) and R (4) independently of one another R (37) -SO cm or R (38) R (39) N-SO 2 -; cm 1 or 2;
  • R (37) (C r C 8 ) alkyl, (C r C 8 ) perfluoroalkyl, (C 3 -C 8 ) alkenyl or -C 3 H 2s R (40); s zero, 1, 2, 3 or 4;
  • R (40) (C 3 -C 8 ) cycioalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (41) R (42); R (41) and R (42)
  • R (51) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (52) R (53); R (52) and R ⁇ 53)
  • R (47), R (48) and R (50) independently are hydrogen, (C r C 4 ) alkyl or (C r C 4 ) perfluoroalkyl;
  • R (49) defines like R (46); or
  • R (68), R (70), R (54) and R (55), identical or different, are hydrogen, (C, -C 6 ) -alkyl; or R (69) and R (70) or R (54) and R (55) together with the carbon atom carrying them is a (C 3 -C 8 ) cycloalkyl; R (63)
  • R (76) -NH-SO 2 -; R (76) R (77) R (78) N- (C - Y ') -; Y' oxygen, S or NR (79); R (77) and R (78) identical or different H, (C r C 8 ) -alkyl, (C 3 -C 6 ) -alkenyl, - C f H 2f -
  • R (80) (C 5 -C 7 ) cycloalkyl or phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methoxy and (C r C 4 ) alkyl; or R (77) and R (78) together 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl, R (79) is defined as R (77) or the same as amidine; or R (3) and R (4) independently of one another NR (84) R (85); R (84) and R (85) independently of one another H, (C ⁇ C ⁇ alkyl, or together 4 or 5 methylene groups, one of which is a CH 2 group by oxygen, S, NH, N-CH 3 or N-benzyl may be replaced; or one or two CH 2 groups of which may be replaced by CH-C dm H 2dm + 1 , and their pharmaceutically acceptable
  • T, U, V, W, X, Y and Z are independently nitrogen or carbon; however with the restriction that X and Z are not nitrogen at the same time and that T, U, V, W, X, Y and Z do not bear a substituent if they
  • RdOa), RdOb), R (11) and R (12) independently of one another (C 1 -C 8 ) alkyl, (C 3 -C 6 ) alkenyl, n zero, 1, 2, 3 or 4;
  • RdOc) and R (13) independently are hydrogen or (C 1 -C 4 ) alkyl; or R (10b) and R (10c) and R (12) and R (13) together 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, sulfur, NH, N-CH 3 or N-benzyl can; or R (3), R (4), R (5), R (6) and R (7) independently of one another (C 1 -C 8 ) -alkyl, -C a
  • Y is oxygen, -S- or -NR (22) -; h, ad, ah independently of one another zero or 1; i, j, k, ae, af, ag, ao, ap and ak independently of one another zero, 1, 2, 3 or 4; however, h, i and k are not simultaneously zero, ad, ae and ag are not simultaneously zero, and ah, ao and ak are not simultaneously zero,
  • R (23), R (24) R (25) and R (22) independently of one another are hydrogen or (C r C 3 ) -alkyl; or R (3), R ⁇ 4), R (5), R (6) and R (7) independently of one another SR (29), -OR (30), -NR (31) R (32) or
  • R ⁇ 32), R (34) and R (35) are independently defined as R (29) or hydrogen, (C r
  • R (96), R (97) and R (98) independently of one another (C, -C 9 ) heteroaryl which is linked via C or N and which is unsubstituted or substituted with 1 to 3 substituents from the group consisting of F. , Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino, dimethylamino or benzyl; W oxygen, S or NR (36) -; R (36) H or (C r C 4 ) alkyl; or R (3), R (4), R (5), R (6) and R (7) independently of one another R (46) X (1) -;
  • R (51) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (52) R (53); R (52) and R (53)
  • R (68), R (70), R (54) and R (55), the same or different, are hydrogen or (C 1 -C 6 alkyl); or R (69) and R (70) or R (54) and R (55 ) together with the carbon atom carrying them (C 3 -C 8 ) -
  • R (56), R (57) and R (73) independently
  • Phenyl which is unsubstituted or substituted by 1-3
  • Y ' is oxygen, S or NR (79); R (77) and R (78) the same or different hydrogen, (C-
  • R (80) (C 5 -C 7 ) cycloalkyl or phenyl which is unsubstituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methoxy and (C r C 4 ) alkyl; or R (77) and R (78) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, sulfur, NH, N-CH 3 or N-benzyl; R (79) is defined as R (77) or the same as amidine; or R (3), R (4), R (5), R (6) and R (7) independently of one another NR (84a) R (85), OR (84b), SR (84c) or -C n H 2n -R (84d); n zero, 1, 2, 3 or 4;
  • R (84d) (C 3 -C 7 ) cycloalkyl or phenyl which is unsubstituted or substituted with 1-3 substituents from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (16) R ⁇ 17 ); R (16) and R (17)
  • R (84a), R (84b), R (84c) and R (85) independently of one another are hydrogen, (C, -C 8 ) -alkyl, (C., - C 8 ) - perfluoroalkyl or (CH 2 ) ax - R (84g); ax zero, 1, 2, 3 or 4;
  • R (84g) (C 3 -C 7 ) -C ⁇ cloalk ⁇ l or phenyl, which is unsubstituted or substituted by 1-3 Substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (84u) R (84v); R (84u) and R (84v)
  • Rd R (6) -SO m ; m zero, 1 or 2;
  • R ⁇ 2) and R ⁇ 3) independently of one another are hydrogen, F, Cl, Br, I, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms or phenoxy, that is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, methyl and methoxy; or
  • R (6) (C r C 8 ) alkyl, (C r C 4 ) perfluoroalkyl, (C 3 -C 8 ) alkenyl, (C 3 -C 8 ) cycloalkyl, phenyl or benzyl; wherein the aromatics are unsubstituted or substituted with 1-3 substituents from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (9) R (10); R (9) and Rd O)
  • R (7) and R (8) are independently defined as R (6); or R (7) and R (8) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, sulfur, NH, N-CH 3 or N-benzyl;
  • R (B) is independently defined as R (A); X is zero, 1 or 2; Y is zero, 1 or 2;
  • R (13) and R (14) independently of one another H, (C 1 -C 4 ) alkyl or (C ⁇ C 4 ) perfluoroalkyl;
  • R (D) is independently defined as R (C),
  • R (2), R (3), R (4) and R (5) are independently defined as Rd); but under the condition that at least one of the substituents R (A), R (B), R (C), R (D), R (1), R (2), R (4) or R (5) is one O r (CH 2 ) a C b F 2b + 1 -, O p (CH 2 ) f C 0 F 2g + 1 - or O t (CH 2 ) d C e F 2 ⁇ + 1 - group and R (3) is not an O t (CH 2 ) d C ⁇ F 2 ⁇ + ⁇ group; and their pharmaceutically acceptable salts; (HOE 94 / F 182 - EP-OS 690 048, NZ 272 449) ac) Ortho-amino-substituted benzoylguanidines of the formula I.
  • R (50) and R (6) independently of one another are hydrogen, (C r C 8 ) -alkyl or (C, -C 8 )
  • R (2), R (3), R (4) and R (5) independently of one another R (10) -SO a -, R (1 1) R (12) N-CO-, R (13) -CO - or
  • RdO R (1 1), R (12), R (13), R (14) and R ⁇ 15) independently of one another (C., - C 8 ) -alkyl, (C r C 8 ) -perfluoroalkyl, (C 3 -C 6 ) alkenyl or -C ab H 2ab -R (16); from zero, 1, 2, 3 or 4; R (16) (C 3 -C 7 ) cycloalkyl, phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy or NR (17) R ( 18); R (17) and R (18) independently of one another H, CF 3 or (C 1 -C 4) alkyl; or R (11), R ⁇ 12), and R (14) and R (15) together 4 or 5 methylene groups, of which one CH 2 group is replaced by oxygen, S, NH, N-CH 3 or N-benzyl can be; or
  • R (21), R (22), R ⁇ 23) and R (25) independently of one another which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; b zero, 1 or 2;
  • R (24), R (26) and R (27) independently of one another are hydrogen, (C, -C 4 ) -alkyl or (C.
  • R (2), R (3), R (4) and R (5) independently of one another hydrogen, F, Cl, Br, I, CN, - (Xa) dg -C da H 2da + 1 , - (Xb ) dh - (CH 2 ) db -C d ⁇ F 2d ⁇ + 1 , (C 3 -C 8 ) alkenyl or -C df H 2df R (30); (Xa) 0, S or NR (33); R (33)
  • Aromatic phenyl, biphenylyl or naphthyl are unsubstituted or substituted with 1-3 substituents selected from the group
  • R (2), R (3), R (4) and R (5) independently of one another NR (40) R (41) or - (Xe) - (CH 2 ) eb R (45); R ⁇ 40) and R (41) independently of one another are hydrogen, (C 1 -C 8 ) -alkyl, (C ⁇ Cg) -perfluoroalkyl or (CH 2 ) ⁇ -R (42); e zero, 1, 2, 3 or 4;
  • R (3) and R (4) cannot be hydrogen, and the pharmaceutically acceptable salts thereof; HOE 94 / F 265 - NZ 272 946, EP-OS 700 904) ad) benzoylguanidines of the formula I.
  • one of the three substituents R (1), R (2) and R (3) (C. -C 9 ) heteroaryl N-oxide which is linked via C or N and which is unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; or one of the three substituents R (1), R (2) and R (3)
  • R (1 1) and R (12) independently defined as R (10), hydrogen or (C r C 4 ) alkyl; and the respective other substituents R (1), R (2) and R (3) independently of one another (C, -C 8 ) alkyl, (C 2 -C 8 ) alkenyl or -C m H 2m Rd4); m zero, 1 or 2;
  • R (14) (C 3 -C 8 ) cycloalkyl or phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (15) R ( 16), R (15) and R (16)
  • R (1), R (2) and R ⁇ 3) independently of one another are hydrogen, F, Cl, Br, I, -C ⁇ N, X- (CH 2 ) p - (C q F 2q + 1 ), R (22) -SO u , R (23) R (24) N-CO, R (25) -CO- or R (26) R (27) N-SO 2 -, the perfluoroalkylene group being straight-chain or is branched; X is a bond, oxygen, S or NR (28); u zero, 1 or 2; p zero, 1 or 2; q zero, 1, 2, 3, 4, 5 or 6;
  • R ⁇ 22), R (23), R (25) and R (26) independently (C r C 8 ) alkyl, (C 2 -C 6 ) alkenyl, -C n H 2n -R (29) or CF 3 ; n zero, 1, 2, 3 or 4;
  • R (28) is hydrogen or (C r C 3 ) alkyl
  • R (29) (C 3 -C 7 ) cycloalkyl or phenyl; which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (30) R (31); R (30) and R (31)
  • R (23) and R (24) and R (26) and R (27) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl ; or the other substituents R (1), R (2) and R (3) independently of one another OR (35) or NR (35) R (36); R (35) and R (36) independently of one another are hydrogen or (C 1 -C 6 alkyl); or R (35) and R (36) together have 4-7 methylene groups, one of which is a CH 2 group by oxygen, S, NH, N-CH 3 or N-benzyl can be replaced, R (4) and R (5) independently of one another hydrogen, (C r C 4 ) alkyl, F, Cl, -OR (32), - NR (33) R ⁇ 34) or C r F 2r + 1 ; R (32), R (33) and R (34) independently of one another are hydrogen or (C 1 -C 3 ) -alkyl; r 1, 2, 3 or 4
  • Rd hydrogen, F, Cl, Br, I, CN, NO 2 , OH, (C r C 8 ) alkyl, (C 3 -C 8 ) cycloalkyl, O a - (CH 2 ) b - (CF 2 ) c -CF 3 ; a zero or 1; b zero, 1 or 2; c zero, 1, 2 or 3; or
  • R (7) is hydrogen or (C r C 4 ) alkyl;
  • R (8) (C 3 -C 7 ) cycloalkyl or phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (9) R ( 10);
  • R (9) and R (10) independently of one another are hydrogen or (C r C 4 ) -alkyl; or R (6) H; or R (6) and R (7) together 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl, or R (1) -SR (1 1), -OR (1 1) or -CR (1 1) R (12) R (13);
  • R (2) -CF 2 R (14), -CF [R (15)] [R (16)], -CF [(CF 2 ) q -CF 3 )] [R (15)], -C [ (CF 2 ) r -CF 3 ] CR (15) R (16);
  • R (15) and R (16) independently of one another are hydrogen or (C r C 4 ) -alkyl;
  • R (3) is defined as Rd); R (4) hydrogen, (C r C 3 ) alkyl, F, Cl, Br, I, CN, - (CH 2 ) s - (CF 2 ) t -CF 3 ; s zero or 1; t zero, 1 or 2; and their pharmaceutically acceptable salts; (HOE 94 / F 267 - EP-OS 700 899, NZ 272 947) af) Benzoylguanidines of the formula I.
  • R (9) is hydrogen or - (C r C 4 ) -alkyl; R (7) -ORdO) or -NR (10) R (1 1); RdO) and R (1 1) independently of one another hydrogen, - (C, -C 8 ) -alkyl, - (C, - C 8 ) -alkanoyl, - (C., - C 8 ) -alkoxycarbonyl, benzyl, benzyloxycarbonyl; or RdO) trityl; R (8) -OR (12) or -NR (12) R (13); R (12) and R (13) independently of one another are hydrogen, - (C 1 -C 8 ) -alkyl or benzyl; k zero, 1, 2, 3 or 4; and the other radicals Rd), R (2) and R (3) independently of one another - ⁇ C j -CgJ alkyl, - (C 2 -C 8 ) alkenyl or
  • Y ' is oxygen, -S- or -NR (20); R (18) and R (19) independently of one another are hydrogen, - (C 1 -C 8 ) -alkyl, - (C 3 -C 6 ) -
  • R (26) R (27) N-SO 2 -, wherein the perfluoroalkyl group is straight-chain or branched;
  • X is a bond, oxygen, -S- or -NR (28); u zero, 1 or 2; p zero, 1 or 2; q 1, 2, 3, 4, 5 or 6;
  • R (22), R ⁇ 23), R (25) and R (26) independently of one another - (C 1 -C 8 ) alkyl, - (C 3 -C 6 ) alkenyl,
  • n zero, 1, 2, 3 or 4;
  • R (28) is hydrogen or - (C r C 3 ) -alkyl
  • R (24) and R (27) independently of one another are hydrogen or - (C 1 -C 4 ) -alkyl; or
  • R (23) and R (24) and R (26) and R (27) together have 4 or 5 methylene groups, of which one CH 2 group is replaced by oxygen, -S-, -NH-, - N-CH 3 or - N-benzyl can be replaced; or the other radicals Rd), R (2) and R (3) independently of one another -OR ⁇ 35) or -NR (35) R (36); R (35) and R (36) independently of one another are hydrogen or - (C., - C 6 ) -alkyl; or R (35) and R (36) together 4-7 methylene groups, of which one CH 2 group can be replaced by oxygen, -S-, -NH-, -N-CH 3 or -N-benzyl; R (4) and R (5) independently of one another are hydrogen, - (C r C 4 ) -alkyl, F, Cl, -OR (32), - NR (33) R (34) or -C r F 2r + 1 ; R (32), R (33) and R
  • R (6) (C r C 8 ) alkyl, (C 1 -C 8 ) perfluoroalkyl, (C 3 -C 8 ) alkenyl or -C n H 2n -R (9), n zero, 1, 2 , 3 or 4;
  • R (9) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (10) R (1 1), RdO) and R (11)
  • R (12) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (13) R (14); R (13) and R (14)
  • R (2) is defined as Rd), or H, OH, F, Cl, Br, I, CN, NO 2 , (C r C 8 ) alk ⁇ l, (C r C 8 ) perfluoroalkyl, (C 3 -C 8 ) alkenyl or -C n H 2n R (15); n zero, 1, 2, 3 or 4;
  • R (19) and R (20) are independently defined as R (18) or hydrogen, (C r C 4 ) alkyl or (C r C 4 ) perfluoroalkyl; or
  • R (29) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (30) R (31); R (30) and R (31)
  • R (23) is hydrogen, (C r C 4 ) alkyl or (C r C 4 ) perfluoroalkyl; or R (22) and R (23) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; or R (2) R (33) X-;
  • M oxygen or S A oxygen or NR (34); DC or SO; R (33) (C r C 8 ) alkyl, (C 3 -C 8 ) alkenyl, (CH 2 ) b C d F 2d + 1 or -C n H 2n - R (36); b zero or 1; d 1, 2, 3, 4, 5, 6 or 7; n zero, 1, 2, 3, or 4;
  • R ⁇ 36) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, Methoxy and NR (37) R (38); R (37) and R (38)
  • R (34) is hydrogen, (C r C 4 ) alkyl or (C 1 -C 4 ) perfluoroalkyl;
  • R (35) defines like R (33); or R (33) and R (34) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; where A and N ⁇ # 1 are bonded to the phenyl nucleus of the benzoylguanidine base body; or
  • R (2) -SR (40), -OR (40), -NHR (40), -NR (40) R (41), -CHR (40) R (42), -CR (42) R (43 ) OH, -C ⁇ CR (45), -CR (46) CR (45) or -ICR (47)
  • R (40) and R (41) independently of one another - (CH 2 ) p - (CHOH) q - (CH 2 ) r - (CHOH) t -R (51) or - (CH 2 ) p -O- (CH 2 -CH 2 O) q -R (51);
  • R (51) is hydrogen or methyl; u 1, 2, 3 or 4; v zero, 1, 2, 3 or 4; p, q and r independently of one another zero, 1, 2, 3 or 4; t 1, 2, 3 or 4;
  • R ⁇ 42) and R ⁇ 43) independently of one another are hydrogen or (C r C 6 ) -alkyl; or R (42) and R ⁇ 43) together with the carbon atom carrying them is a (C 3 -C 8 ) cycloalkyl; R (44) hydrogen, (C r C 6 ) alkyl, (C 3 -C 8 ) cycloalkyl, -C ⁇ H 2 ⁇ -R (45); e zero, 1, 2, 3 or 4;
  • R (45) phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (52) R (53); R ⁇ 52) and R (53)
  • Y is oxygen, S or N-R (58);
  • R (56) and R (57) independently of one another hydrogen, (C 1 -C 8 ) alkyl, (C 3 -C 6 ) alkenyl or -C f H 2f -R (59); f zero, 1, 2, 3 or 4;
  • R (59) (C 5 -C 7 ) cycloalkyl, phenyl, which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methoxy and (C., - C 4 ) - Alkyl; or R (56) and R ⁇ 57) together 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; R (58) is defined as R (56) or the same as amidine; R ⁇ 3), R (4) and R (5) are defined independently of one another like R ⁇ 1) or R (2), but at least one of the substituents R (2), R (3), R (4) and R (5) must be equal to OH; and their pharmaceutically acceptable salts; (HOE 95 / F 007 K - EP-OS 723 956, NZ 280 887) ah) Benzoylguanidines of the formula I.
  • R (6) a basic heteroaromatic ring system with 1-9 C atoms; AC b H 2b ; b 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; where in the group C b H 2b one or two methylene groups are selected by one of the groupings from the group consisting of -0-, -CO-, -CH [OR (20)] -, -SO m -, -NR (20) -, -NR (20) -CO-, -NR (20) -CO-NH-, -NR (20) -CO-NH-SO 2 -
  • R (19) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms
  • R (20) is hydrogen or methyl; a phenylene or naphthylene radical,
  • R (12) and R (13) independently of one another are hydrogen, methyl, F, Cl, Br, J, CF 3 or -SO w -R (14);
  • R (15) and R (16) independently of one another are hydrogen or alkyl having 1, 2,
  • R (21) is hydrogen or methyl; m zero, 1 or 2; and the other substituents R (1) and R (2) and R (3) independently of one another are hydrogen, F, Cl, Br, J, -CN, - (C r C ⁇ ) -alkyl, - (C 2 - C 8 ) -alkenyl, -NR (35) R (36) or R (17) -C 8 H 2g -Z h -; g zero, 1, 2, 3 or 4; h zero or 1;
  • R (35) and R (36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms; or R (35) and R (36) together 4-7 methylene groups, of which one CH 2 group can be replaced by oxygen, -S-, -NH-, -NCH 3 or -N-benzyl; Z -O-, -CO-, -SO v -, -NR (18) -, -NR (18) -CO-, -NR (18) -CO-NH- or -NR (18) -SO 2 - ;
  • R (18) is hydrogen or methyl; v zero, 1 or 2; R ⁇ 17) hydrogen, cycloalkyl with 3, 5 or 6 carbon atoms or C k F 2k + 1 -; k 1, 2 or 3, or R (17) pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is unsubstituted or substituted with 1-4 substituents selected from the group consisting of F, Cl , Br, I, -CN, (C 2 -C 8 ) alkanoyl, (C 2 -C 8 ) alkoxycarbonyl, formyl, carboxy, -CF 3 , methyl and methoxy; or R (17) - (C 3 -C 8 ) -cycloalkyl or phenyl, which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F and Cl, -CF 3 , methyl, hydroxy, methoxy, -NR (37) R (38),
  • R (4) and R (5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR (32 ⁇ -NR (33) R (34) or -C r F 2r +1 ; R (32), R (33) and R (34) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms; r 1, 2, 3 or 4; and their pharmacologically acceptable salts; (HOE 95 / F 072 - EP-OS 738 712, NZ 286 380 ai) indenoylguanidines of the formula I.
  • Rd) and R (2) independently of one another hydrogen, alkyl with 1, 2, 3, 4, 5, 6, 7, 3, 9 or 10 carbon atoms, cycloalkyl with 3, 4, 5 or 6 carbon atoms.
  • O-alkyl with 1, 2, 3 or 4 carbon atoms, OC ( O) alkylene with 1, 2, 3 or 4 carbon atoms or C m H 2m -NR (12) R (13);
  • R (12) and R (13) independently of one another hydrogen or alkyl with 1, 2, 3 or 4 C-
  • Rd), R (2) and R (3) independently of one another are -Y- [4-R (8) -phenyl], -Y- [3-R (8) -phenyl] or -Y- [2 - R (8) -phenyl], the phenyl in each case being unsubstituted or substituted by 1 -
  • R (96) and R (97) independently of one another are hydrogen or -CH 3 ;
  • Y is a bond, CH 2 , oxygen, -S- or -NR (9);
  • R (9) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
  • R (8) SO a [NR (98)] b NR (99) R (10); a 1 or 2; b 0 or 1; a + b 2;
  • R (98), R (99) and R (10) independently of one another are hydrogen, - (C r C 8 ) -alkyl, benzyl,
  • R (11), R (12), R (13), R (37), R (38), R (43) and R (44) independently of one another are hydrogen, - (C, -C 8 ) -alkyl or benzyl : R (39), R (40), R (41) and R (42) independently of one another hydrogen, - (C 1 -C 8 ) -alkyl or - (C 0 -C 3 ) -alkylene-phenyl, where the Phenyl is not substituted or substituted with 1-3 substituents selected from the group consisting of F, CI, -CF 3 , methyl and methoxy; or R (99) and R (10) together 4-6 methylene groups, of which one CH 2 group can be replaced by oxygen, -S-, -NH-, -N-CH 3 or -N-benzyl; or
  • R (8) SO a [NR (98)] b NR (95) -C [ NR (94) ⁇ - NR (93) R (92); R (92), R (93), R (94) and R (95) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or Rd), R (2) and R (3) independently of one another pyrrol-1 -yl, pyrrol-2-yl or pyrrol-3-yl, which is not substituted or substituted with 1-4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C 2 -C 8 ) alkanoyl, (C 2 -C 8 ) alkoxycarbonyl, formyl, carboxy, -CF 3 , methyl, methoxy; or R (1), R ⁇ 2) and R (3) independently of one another are hydrogen, - (C 1 -C 8 ) -alkyl, - (C 2 -C 8 ) -alkenyl or - (CH
  • R (18) is hydrogen or - (C r C 4 ) -alkyl; R (17) -OR (21) or -NR (21) R (22); R (21) and R (22) independently of one another are hydrogen, - (C, -C 8 ) -alkyl, - (C, - C 8 ) -alkanoyl, - (C ⁇ CgJ-alkoxycarbonyl, benzyl, benzyloxycarbonyl; or R (21) trityl; R (20) -OR (23) or -NR (23) R (24);
  • R (23), R (24) independently of one another
  • R (26) and R (27) independently of one another are defined as R (25) or hydrogen or (C r C 4 ) -alkyl, or Rd), R (2) and R (3) independently of one another (C., - C 9 ) -Heteroaryl-N-oxide which is linked via C or N and which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; or R (1), R (2 ⁇ and R (3) independently of one another -SR (28), -OR (28), -NR (28) R (29) or
  • R (28) -C 8 H 2fl - (C 1 -C 9 ) heteroaryl-N-oxide which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , Methoxy, hydroxy, amino, methylamino and dimethylamino; g zero, 1 or 2;
  • T is a bond, oxygen, -S- or -NR ⁇ 47);
  • I zero, 1 or 2; h zero, 1 or 2; i 1, 2, 3, 4, 5 or 6;
  • R (31), R ⁇ 32), R (34) and R (45) independently of one another - (C 1 -C 8 ) alkyl, - (C 3 -C 6 ) alkenyl,
  • R (47) is hydrogen or alkyl having 1, 2 or 3 carbon atoms
  • R (33) and R (46) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or R (32) and R (33) and R (45) and R (46) together 5 or 6 methylene groups, one of which is a CH 2 group by oxygen, -S-, -NH-, -NCH 3 or -N -Benzyl can be replaced; or Rd), R (2) and R (3) independently of one another R (51) -AGD-;
  • R (51) is a basic protonatable residue, i.e. an amino group
  • R (52), R (53), R (54) and R (55) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4
  • R (56) is hydrogen or methyl
  • R (51) is a basic heteroaromatic ring system with 1 - 9 C atoms;
  • A is a group C ⁇ H 2e ; e zero, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; where in the group C ⁇ H 2e a C atom is one of the groupings -O-, -CO-, -CH [OR (57)] -, -SO r -, -NR (57) -, -NR (57 ) - CO-, -NR (57) -CO-NH-, -NR (57) -CO-NH-SO 2 - or -NR (57) -SO 2 - can be replaced; r zero, 1 or 2;
  • G is a phenylene radical
  • R (58) and R ⁇ 59) independently of one another hydrogen, methyl, methoxy, F, Cl, Br, J, CF 3 or -SO s -R (60); R (60) methyl or NR (61) R (62); R (61) and R (62) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; -C v H 2v -E w -; v zero, 1, 2, 3 or 4;
  • R (63) is hydrogen or methyl, or Rd), R (2) and R (3) independently of one another -CF 2 R (64), -CF [R (65) HR (66)], -CF [(CF 2 ) q -
  • R ⁇ 65) and R (66) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; q zero, 1 or 2; p zero, 1 or 2; or R (1), R (2) and R (3) independently of one another -OR (67) or -NR (67) R (68);
  • R (67) and R (68) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms; or R (67) and R (68) together 4, 5, 6 or 7 methylene groups, one of which is CH 2 -
  • Group can be replaced by oxygen, -S-, SO 2 , -NH-, -NCH 3 or -N-benzyl;
  • R (4) and R (5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR (69), -NR (70) R (71) or -C 2 F 2z + 1 ;
  • R (69), R (70) and R (71) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms.
  • Atoms; z 1, 2, 3 or 4; R (6) and R (7) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms.
  • X is oxygen or NR (72);
  • R ⁇ 72 is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; and their pharmaceutically acceptable salts; (HOE 95 / F 115 - EP 744 397, NZ 286 622) al) alkenylcarboxylic acid guanidides of formula I bearing fluorophenyl groups
  • R (6) is hydrogen, (C r C 8 ) -alkyl, (C 3 -C 8 ) -cycloalkyl or phenyl, the phenyl group not being substituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (9) R (10); R (9) and RdO)
  • R (7) is independently defined as R (6); Rd),
  • R (2), R (3), R (4) and R (5) independently of one another are hydrogen or F; however, at least one of the radicals R (1), R (2), R (3), R (4) and R (5) must be fluorine; and their pharmaceutically acceptable salts; (HOE 95 / F 167 - NZ 299 015) am) benzoylguanidines of the formula I
  • Rd R (4) -SO m or R (5) R (6) N-SO 2 -; m 1 or 2; R (4) and R (5) independently of one another alkyl with 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl with 3, 4, 5 or 6 carbon atoms, CF 3 or -C n H 2n -R (7); n zero, 1, 2, 3 or 4;
  • R (6) is H or alkyl having 1, 2, 3 or 4 carbon atoms; R (7) cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (8) R (9); R (8) and R (9)
  • R (5) is also hydrogen; or R (5) and R (6) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; or
  • R (3) defines hydrogen or independently as Rd); and their pharmaceutically acceptable salts; (HOE 95 / F 173 - NZ 299 052) an) Substituted cinnamic acid guanidides of the formula I.
  • R (16), R (17) and R (18) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; a zero or 1;
  • alkylene with 1, 2, 3, 4, 5, 6, 7 or 8 C atoms
  • alkylene T with 1, 2, 3, 4, 5, 6, 7 or 8 C atoms in the alkylene group
  • T, T-alkylene with 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group
  • T NR (20) 0, S or phenylene, where the phenylene is unsubstituted or substituted with 1 -3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and
  • R (20), R (21) and R (22) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; b zero or 1; LO, S, NR (23) or C k H 2k ; k 1, 2, 3, 4, 5, 6, 7, 8; n zero or 1;
  • R (24) and R (25) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl; wherein the N-containing heterocycles are N- or C-bridged and are not substituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (27) R (28); R (23), R (27) and R (28) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; and the respective other substituents R (1), R (2), R (3), R (4) and R (5) independently of one another H, F, Cl, Br, I, CN, -O n -C m H 2m + 1 , -O p - (CH 2 ) s -
  • R (7) is hydrogen or methyl
  • R (8) and R (9) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl which is unsubstituted or substituted is selected with 1-3 substituents on the group consisting of F, Cl, CF 3 , methyl and methoxy; or the other substituents R (1), R (2) and R (3) independently of one another phenyl, C 6 H 5 - (C 1 -C 4 ) alkyl, naphthyl, biphenylyl, quinolinyl, isoquinolinyl or imidazolyl, where quinolinyl, Isoquinolinyl or imidazolyl are bonded via C or N, and where phenyl, C 6 H 5 - (C 1 -C 4 ) alkyl, naphthyl, biphenylyl, quinolinyl, isoquinolinyl and imidazolyl are un
  • R (1 1) and R (12) are independently defined as R (10), hydrogen or
  • R (4) and R (5) independently of one another are hydrogen, alkyl having 1, 2 or 3 carbon atoms, F,
  • R (13), R (14) and R (15) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4
  • At least one of the three substituents R (1), R (2) and R (3) is a benzoylguanidine
  • O which is unsubstituted or substituted in the phenyl part with 1-4 radicals selected from the group consisting of alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl having 2, 3, 4, 5, 6 , 7 or 8 carbon atoms, - (CH 2 ) m -R (14), F, Cl, Br, I, -C ⁇ N, CF 3 , R (22) SO 2 -, R (23) R (24) N-CO-, R (25) -CO-, R (26) R (27) N-SO 2 , -OR (35), -SR (35) or -NR (35 ) R (36); m zero, 1 or 2; R (14)
  • R (16 ) independently of one another are hydrogen or - CH 3 ;
  • R (22), R (23), R (25) and R (26) independently of one another are alkyl having 1, 2, 3, 4, 5, 6, 7 or 8
  • R (24) and R (27) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or
  • R (23) and R ⁇ 24) and R (26) and R ⁇ 27) together have 5 or 6 methylene groups, one of which is a CH 2 group through oxygen, -S-, -NH-, -NCH 3 or -N- Benzyl can be replaced;
  • Phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, -CF 3 , methyl, methoxy, SO 2 R (5), SO 2 NR (6) R (7) and - NR (32) R (33); R (5) alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms R (6) and R (7) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; R (32) and R ⁇ 33) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or R ⁇ 35)
  • R (2) and R (3) independently of one another are alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms,
  • Rd O phenyl, which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, -CF 3 , methyl, methoxy, -SO 2 NR (17) R (8) and -SO 2 R ⁇ 9); R (17) and R ⁇ 8) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; R (9) alkyl having 1, 2, 3 or 4 carbon atoms; or the other remainder Rd) and R (3)
  • R (8); R (7) and R (8) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms.
  • R (2) is hydrogen or alkyl having 1, 2, 3, 4, 5 , 6, 7 or 8 carbon atoms or -SO 2 R (9)
  • R (9) is defined independently as Rd);
  • R (3) is hydrogen, -SR (25), -OR (25), -NR (25) R (26) or -CR (25) R (26) R (27);
  • R (25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, or phenyl which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; or R (25)
  • R (1) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, -OR (32),
  • R (32), R (33) and R (34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; R (2) and R ⁇ 4) independently of one another hydrogen, F, Cl, Br, I, OH, -CN, CF 3 ,
  • -CO-N C (NH 2 ) 2 , alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 C- Atoms or - (CH 2 ) m R (14); m zero, 1 or 2;
  • R (2) and R (4) independently of one another pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is unsubstituted or substituted with 1-4 substituents selected from the group consisting of F, Cl , Br, I, -CN, (C 2 -C 8 ) alkanoyl, (C 2 -C 8 ) alkoxycarbonyl, formyl, carboxy, -CF 3 , methyl, methoxy; or R ⁇ 2) and R (4) independently of one another R (22) -SO 2 -, R (23) R (24) N-CO-, R (28) -CO- or
  • R (22) and R (28) independently of one another are methyl or -CF 3 ;
  • R (35) and R (36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms; or
  • R (25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF. 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; or R (25) - (C, -C 9 ) heteroaryl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and Dimethylamino; R (26) and R (27) independently of one another are defined as R (25) or hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; R (5) alkyl with 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, X- (CH 2 ) y -CF 3 or phenyl, which is unsubstituted
  • R ⁇ 25 is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF. 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; or R (25 - (C 1 -C 9 ) heteroaryl, which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino
  • R (26) and R (27) independently of one another are defined as R ⁇ 25) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; R (4) CF 3 , alkyl with 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, alkenyl with 2, 3, 4, 5, 6, 7 or 8 C atoms, - (
  • R (32), R (33) and R (34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; the other radicals R (2) and R (4) independently of one another hydrogen, F, Cl, Br, I, OH, -CN, CF 3 ,
  • -CO-N C (NH 2 ) 2 , alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 C- Atoms or - (CH 2 ) m R (14); m zero, 1 or 2;
  • R (35> and R (36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms; or
  • R (25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.
  • R (25) - (C r C 9 ) heteroaryl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino
  • R (26) and R (27) independently of one another are defined as R (25) or hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; one of the residues R ⁇ 6), R (7), R (8), R (9) and RdO)
  • -CO-N C (NH 2 ) 2 ;
  • the other radicals R (6) and R (10) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR (132), -NR (133) R (134) or CF 3 ;
  • R (132), R (133) and R (134) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
  • the other radicals R (7) and R (9) independently of one another hydrogen, F, Cl, Br, I, OH, -CN, CF 3 , -CO-N C (NH 2 ) 2 , alkyl with 1, 2, 3, 4, 5, 6, 7 or 8 C. Atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 carbon atoms or - (CH 2 ) mm R (1 14); mm zero, 1 or 2;
  • R (135) and R (136) together have 4-7 methylene groups, of which one CH 2 group can be replaced by oxygen, -S-, -NH-, -NCH 3 or -N-benzyl; the other R (8)
  • R (126) and R ⁇ 127) independently of one another as R (125) defined or hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
  • a absent, -NR (1 1) -CO-, -NR (12) -CO-NR (13) -, -NR (17) -CO-NR (18) -SO 2 -, - NR (19) - SO 2 -, -SO 2 -NR (19) -SO 2 -NR (19) -CO 2 -NR (19) -CO 2 -NR (19) -CO-, -O-CO-NR (19) -SO 2 - or -CR (20) CR (21) -; R (1 1), R (12), R (13), R (17), R (18), R (19), R (20) and R (2
  • R (41) and R (42) independently of one another hydrogen, alkyl with 1, 2, 3 or 4 carbon atoms, perfluoroalkyl with 1, 2, 3 or 4 carbon atoms, or R (41) and R (42) together 4 or 5 methylene groups, one of which is CH 2 - group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; and the respective other substituents R (1), R (2) and R (3) independently of one another H, F, Cl, Br, I, CN, -O na -C ma H 2ma + 1 or -
  • RdO cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, the phenyl being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl and methoxy
  • R (4) and R (5) independently of one another are hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl with 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl which is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of from F, Cl, CF 3 , methyl, methoxy and NR (14)
  • R (15); R (14) and R (15) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon
  • R (2) and R (3) independently of one another hydrogen, Cl, Br, I, (C-
  • R (5) (-C -C ⁇ ) alkyl or -C d H 2d - (C3-C8) cycloalkyl; d zero, 1 or 2; where one of the two substituents R (2) and R (3) is always hydrogen, but not both substituents R (2) and R (3) are simultaneously hydrogen, and their pharmaceutically acceptable salts; (HOE 96 / F 042) ax) Benzoylguanidines of the formula I
  • X is oxygen, S, NR (5), a zero or 1; b zero, 1 or 2; c zero, 1, 2 or 3; R (5) H, alkyl having 1, 2, 3 or 4 carbon atoms or -C d H 2d R (6); d zero, 1, 2, 3 or 4;
  • R (6) cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, phenyl, biphenylyl or naphthyl, the aromatics phenyl, biphenylyl or naphthyl being unsubstituted or substituted with 1-3 substituents selected from the group consisting of from F, Cl, CF3, methyl, methoxy and NR (7) R (8); R (7) and R (8) independently are H or alkyl having 1, 2, 3 or 4 carbon atoms; or R (1) -SR (10), -OR (10) or -CR (10) R (11) R (12);
  • R (11) and R (12) independently of one another are defined as R (10) or hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or
  • R (13) and R (14) the same or different - (CH2) g- (CHOH) h - (CH2) r (CHOH) r R (17) or - (CH2) gO- (CH2-CH2 ⁇ ) hR (24 ), R (17) hydrogen or methyl, g, h and i, identical or different, zero, 1, 2, 3 or 4, j 1, 2, 3 or 4,
  • R (15) and R (16), the same or different, are hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, or together with the carbon atom carrying them cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, R (18)
  • Phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR (25) R (26), R (25) and R (26)
  • Rd H, F, Cl, Br, I, CN, NO2, alkyl with 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkoxy with 1, 2, 3, 4, 5, 6 , 7 or 8 carbon atoms, cycloalkyl with 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkoxy with 3, 4, 5, 6, 7 or 8 carbon atoms or X a - (CH2) b- (CF2) c-CF 3 ; X is oxygen, S, NR (5), a zero or 1; b zero, 1 or 2; c zero, 1, 2 or 3;
  • R (5) H, alkyl having 1, 2, 3 or 4 carbon atoms or -C d H 2d R (6); d zero, 1, 2, 3 or 4;
  • R (6) cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms, phenyl, biphenylyl or naphthyl, the aromatics phenyl, biphenylyl or naphthyl being unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR (7) R (8); R (7) and R (8) independently are H or alkyl having 1, 2, 3 or 4 carbon atoms; or Rd) -SR (IO), -ORdO) or -CR (10) R (1 1) R (12);
  • R (11) and R (12) independently of one another are defined as RdO) or are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or
  • R (1) phenyl, naphthyl, biphenylyl or heteroaryl with 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms, the latter linked via a carbon or nitrogen atom of the ring, each of which is unsubstituted or are substituted with 1-3 substituents selected from the group consisting of F, Cl, CF3, CH3, methoxy, hydroxy, amino, methylamino and dimethylamino, or Rd) -SR (13), -OR (13), -NHR ( 13), -NR (13) R (14), -CHR (13) R (15),
  • R (13) and R (14) the same or different - (CH2) g - (CHOH) h - (CH 2 ) j- (CHOH) jR (17) or - (CH 2 ) gO- (CH2-CH 2 O ) h -R (24);
  • R (17) is hydrogen or methyl, g, h and i, identical or different, are zero, 1, 2, 3 or 4; j 1, 2, 3 or 4; and
  • R (16), the same or different, is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, or together with the carbon atom carrying it, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms ;
  • Phenyl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF3, methyl, methoxy and NR (25) R (26); R (25) and R (26)
  • W, Y and Z represent a nitrogen atom or a C atom substituted by R (2) or R (3) or R (4); Rd) hydrogen, A, Hal, -CF3, -CH2F, -CHF 2 , -CH 2 CF 3 , -C 2 F 5 , -CN, -NO2,
  • Ethinyl or an X-R '; A alkyl with 1 to 6 carbon atoms;
  • X is oxygen, S or NR ";
  • R " is hydrogen, A or a cyclic methylene chain with 3 to 7 C atoms; R 'H, A, HO-A, HOOC-A, (C 3 -C 7 ) cycloalkyl, (C 6 -C 8 ) -Cycloalkyl- alkyl, CF 3 , CH 2 F, CHF 2 , CH 2 -CF 3 , Ph, -CH 2 -Ph or Het; Ph unsubstituted or one, two or three times by A, OA, NR'R ", Hal, CF3 substituted phenyl, naphthyl, or biphenylyl; Het is a mono- or dinuclear saturated, unsaturated or aromatic heterocycle with 1 to 4 N, O, and / or S atoms, which is unsubstituted or mono-, di- or trisubstituted by Hal, CF3, A, OH, OA, -X-R ', -CN,
  • R (2) and R (3) independently of one another R (5) -O-;
  • R (5) is hydrogen, A, (C r C 6 ) alkenyl or (C 3 -C 7 ) cycloalkyl;
  • R (2) in the meaning given;
  • R (6), R (7), R (8) and R (9) independently of one another H or A; or
  • R (8) (C 5 -C 7 ) cycloalkyl
  • R (9) cyano; Alk straight-chain or branched (C 1 -C 8 ) alkyl or (C 3 -C 8 ) cycloalkyl, which is unsubstituted or substituted by A once, twice or three times; or Alk is an ethenyl or ethynyl radical substituted by H, A, Ph or Het; (DE 41 27 026, DE 4337609, JP 07025768, Edward J. Cragoe, Jr.,
  • Z is an amino group -NR (1) R (2);
  • H a mono- or polynuclear heterocycle containing nitrogen, oxygen or sulfur atoms, which is unsubstituted or substituted with H, Hal or (C r C 4 ) alkyl; a phenyl radical, unsubstituted or substituted by a substituent selected from the group consisting of (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, Hal and OH; or R (2) 1 -piperidino, unsubstituted or substituted in the 4-position by an acyl radical of an aliphatic, alicyclic, aromatic or heteroaromatic carboxylic acid, (C r C 8 ) alkyl, which in turn can be substituted by OH or (C1 - C4) alkoxy or a (C 1 -C 4 ) alkoxy-substituted phenyl radical; or R (2) amidino which is unsubstituted or substituted with phenyl which is unsubstitute
  • R (2) hydrogen, unsubstituted or substituted (C 1 -C 8 ) alkyl, (C 3 -C 7 > cycloalkyl, OH, ⁇ C, -C 6 ) alkyl-O-, an aromatic radical or a group -CH2-R (20);
  • R (3) hydrogen, (C r C 8 ) -alkyl, substituted (C r C 8 ) -alkyl, (C 3 -C 7 > - cycloalkyl, an aromatic radical or a group -CH2-ROO) R (30) Alkenyl or alkynyl; R (6) and R ⁇ 7) independently of one another hydrogen, unsubstituted or substituted (C r C 8 ) alkyl, (C 3 -C 7 ) cycloalkyl, (C 2 -C 8 ) alkanoyl, an arylalkano ⁇ l group with up to 10 C atoms, an aroyl group with up to 1 1 C atoms, an aromatic group or -CH2- R (60);
  • R (50) is hydrogen or ⁇ C r C 8 ) alkyl;
  • R ' is hydrogen, unsubstituted or substituted (C, -C 8 ) alkyl, in which the ring represents a saturated 3-8 membered heterocycle with an N atom, said substituted alkyl carries one or more groups selected from the group consisting of halogen, -OH, (C, -Cg) alkoxy, -CN, -COOH, (C 2 -C 6 ) alkoxycarbonyl, (C 2 -C 8 ) alkanoyl, arylalkanoyl with up to 10 C atoms, aroyl with up to 1 1 carbon atoms, an aromatic group, -CONR (4) (R5), R (4) and R (5), the same or different, hydrogen or (C 1 -C 8 ) alkyl; or R (4) and R (5) are bonded to one another and together form a 5-7-membered cyclic amine
  • E is an N atom or a CH group
  • R is hydrogen, unsubstituted or substituted by OH (C 1 -C 8 ) -
  • R (4) and R (5) independently of one another are hydrogen or (C 1 -C 8 ) -alkyl; the cyclic system of
  • Atoms a 5- or 6-membered heteroaryl radical with 1 -4 N atoms, a 5- or 6-membered heteroaryl group containing 1 or 2 N atoms and one
  • Aralkyl which is unsubstituted or substituted by one or more substituents from the groups halogen, (C r C 4 ) -alkyl, (C 1 -C 4 ) -alkyl-O- or -CF 3 , - (CH 2 ) m -CH 2 -T, m zero to 3; T -CO-OT ⁇ 1);
  • T hydrogen or (C1 -C4) alkyl; a benzo-fused unsaturated or dihydro-5 ring heterocycle
  • R (6) hydrogen, halogen, hydroxy, (C r C 10 ) -alkyl, (C r C 10 ) -alkyl-O-, phenoxy, (C r C 10 ) -alkyloxymethyloxy- or - (O) n SR ( 9); R (9) (C r C 10 ) alkyl, thienyl, pyridyl, thiazolyl, thiadiazolyl, imidazolyl, pyrazolyl or phenyl which are unsubstituted or mono- or disubstituted by halogen, (C r C 4 ) -alkyl or ( C r C 4 ) alkyl-O-; R (7) and R (8) Hydrogen, halogen, hydroxy, (C r C 10 ) alkyl, (C r C 10 ) alkyl-O-, phenyl, phenoxy or (C r C 10 ) alkoxymethyloxy; or
  • R (12) is a single bond, -O-, - (O) n S-, -CO- or -CONH-;
  • R (13) is a single bond, phenyl, thienyl, pyridyl, thiazolyl,
  • R (14) is a single bond SO2-;
  • RdO hydrogen, (C r C 4 ) -alkyl or benzyl
  • R (1 1) (C r C 4 ) alkyl, phenyl or benzyl; or
  • RdO) and R (1 1) together form a (C 3 -C 10 ) alkylene group which is unsubstituted or substituted by -COOH, (C r C 5 ) alkoxycarbonyl, (C 2 -C 4 ) hydroxyalkylene or benzyl; or
  • NHE exchange inhibitors of subtype 3 are preferably used:
  • Y is oxygen, S or NR (7); A, B together a bond or
  • R (9) H, methyl, ethyl,
  • W is oxygen or NR (10);
  • RdO H or methyl; y zero or 1; or
  • R (1 1) H or methyl; or Z oxygen or -NR (12) -;
  • R (13) H or (C r C 4 ) alkyl; R ⁇ 7) hydrogen, (C r C 10 ) alkyl, (C 2 -C 10 ) alkenyl or R (8) -C n H 2n -; and their pharmaceutically acceptable salts;
  • Rd H, (C r C 8) -alkyl, unsubstituted or substituted by hydroxy, (C 3 -C 8 ) cycloalkyl, phenyl which is unsubstituted or substituted with 1-3 substituents from the group F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino or dimethylamino,
  • R (6) hydrogen, (C r C 8 ) alkyl, (C 3 -C 8 ) alkenyl, (C 3 -C 8 ) cycloalkyl, phenyl or benzyl, the aromatics being unsubstituted or substituted by 1 - 3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (9) R (10); R (9) and R (10)
  • R (7) and R (8) are independently defined as R (6);
  • R (B) is independently defined as R (A); X 1, 2 or 3;
  • Rd hydrogen, (C r C 8 ) alkyl, (C 3 -C 8 ) cycloalkyl, -O t (CH 2 ) d C e F 2 ⁇ + 1 , F, Cl,
  • R (2), R (3), R (4) and R (5) are independently defined as R (1); but under the condition that at least one of the substituents R (1), R (2), R (3), R (4), R (5), R (A) and R (B) has an -O t (CH 2 ) d is C ⁇ F 2 ⁇ + 1 or an O r (CH 2 ) a C b F 2b + 1 group, and their pharmaceutically acceptable salts;
  • T, U, V, W, X, Y and Z are independently nitrogen or carbon; however with the restriction that X and Z are not nitrogen at the same time and that T, U, V, W, X, Y and Z do not bear a substituent if they
  • Group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; R (3), R (4), R (5), R (6) and R (7) independently of one another hydrogen, F, Cl, Br, I, -C ⁇ N, X k - (CH 2 ) p - (C q F 2q + 1 ), R (10a) -SO bm .
  • X is oxygen, S or NR (14 );
  • R (14) H or C r C 3 ) alkyl; bm zero, 1 or 2; p zero. 1 or 2; k zero or 1; q 1, 2, 3, 4, 5 or 6; RdOa), Rd Ob), R (11) and R (12) independently of one another ⁇ -C 8 ) alkyl, (C 3 -C 6 ) alkenyl,
  • RdOc) and R (13) independently are hydrogen or (C 1 -C 4 ) alkyl; or R (10b) and R (10c) and R (12) and R (13) together 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, sulfur, NH, N-CH 3 or N-benzyl can; or R (3), R (4), R (5), R (6) and R (7) independently of one another (C 1 -C 8 ) -alkyl, -C a
  • Y is oxygen, -S- or -NR (22) -; h, ad, ah independently of one another zero or 1; i, j, k, ae, af, ag, ao, ap and ak independently of one another zero.1, 2, 3 or 4; however, h, i and k are not simultaneously zero, ad, ae and ag are not simultaneously zero, and ah, ao and ak are not simultaneously zero,
  • R (23), R (24) R (25) and R (22) independently of one another are hydrogen or (C r C 3 ) -alkyl; or R (3), R (4), R (5), R (6) and R (7) independently of one another SR (29), -OR (30), -NR (31) R (32) or
  • R ⁇ 29), R (30), R (31) and R (33) independently of one another -C a H 2a - (C 1 -C 9 ) heteroaryl which is unsubstituted or substituted with 1 - 3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, Methylamino and dimethylamino; a zero, 1 or 2;
  • R (32), R (34) and R (35) independently of one another are defined as R (29) or hydrogen, (C, -
  • R (96), R (97) and R (98) independently of one another (C ⁇ CgJ heteroaryl which is linked via C or N and which is unsubstituted or substituted with 1 to 3 substituents from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino, dimethylamino or benzyl;
  • R (51) (C 3 -C 8 ) -cycloalkyl, phenyl, biphenylyl or naphthyl, the aromatics being unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (52) R (53); R (52) and R (53)
  • R (71) and R (72) independently of one another are hydrogen or methyl; u 1, 2, 3 or 4; v zero, 1, 2, 3 or 4; y, z, aa the same or different zero, 1, 2, 3 or 4; t 1, 2, 3 or 4;
  • R (68), R (70), R (54) and R (55), identical or different, are hydrogen or (C 1 -C 6 -alkyl); or R (69) and R ⁇ 70) or R (54) and R (55) together with the carbon atom carrying them a (C 3 -C 8 ) -
  • Phenyl which is unsubstituted or substituted by 1-3
  • R ⁇ 77) and R (78), the same or different, are hydrogen, (C 1 -C 8 ) alkyl, (C 3 -C 6 ) alkenyl or -C f H 2f -R (80); f zero, 1, 2, 3 or 4;
  • R (80) (C 5 -C 7 ) cycloalkyl or phenyl, which is unsubstituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methoxy and (C 1 -C 4 ) alkyl; or R (77) and R (78) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, sulfur, NH, N-CH 3 or N-benzyl; R (79) is defined as R (77) or the same as amidine; or R (3), R (4), R (5), R (6) and R (7) independently of one another NR (84a) R (85), OR (84b), SR (84c) or -C n H 2n -R (84d); n zero, 1, 2, 3 or 4;
  • R (84d) (C 3 -C 7 ) cycloalkyl or phenyl, which is unsubstituted or substituted with 1-3 substituents from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (16) R (17th ); R (16) and R (17)
  • R (84a), R (84b), R (84c) and R (85) independently of one another are hydrogen, (C 1 -C 8 ) -alkyl, ⁇ C * -C 3 ) -perfluoroalkyl or (CH 2 ) ax -R (84g); ax zero, 1, 2, 3 or 4;
  • R (84g) (C 3 -C 7 ) cycloalkyl or phenyl, which is unsubstituted or substituted by 1-3 Substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (84u) R (84v); R (84u) and R (84v)
  • R (84a) and R (85) together 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, sulfur, NH, N-CH 3 or N-benzyl, and their pharmaceutically acceptable salts;
  • R (7) and R (8) are independently defined as R (6); or R (7) and R (8) together have 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, sulfur, NH, N-CH 3 or N-benzyl;
  • R (B) is independently defined as R (A); X is zero, 1 or 2; Y is zero, 1 or 2;
  • R ⁇ 2), R (3), R (4) and R (5) are independently defined as R (1); but under the condition that at least one of the substituents R (A), R (B), R (C), R (D), R (1), R (2), R (4) or R (5) is one O r (CH 2 ) a C b F 2b + 1 -, O p (CH 2 ) f C g F 2g + 1 - or O t (CH 2 ) d C e F 2 ⁇ + 1 - group and R ⁇ 3) is not an O t (CH 2 ) d C e F 2e + 1 group; and their pharmaceutically acceptable salts; (HOE 95 / F 007 K - EP-OS 723 956, NZ 280 887) ah) Benzoylguanidines of the formula I.
  • R (8) and R (9) or R (9) and R (10) or R (7) and R ⁇ 10) a group C a H 2a ; a 2, 3, 4 or 5; where in the case of a 3, 4 or 5 a methylene group of the group C a H 2a can be replaced by a hetero atom group O, SO m or NR (11); m zero, 1 or 2; R (11) is hydrogen or methyl; or
  • R (6) a basic heteroaromatic ring system with 1-9 C atoms; AC b H 2b ; b 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; wherein in group C b H 2b one or two methylene groups are selected by one of the groupings from the group consisting of -O-, -CO-, -CH [OR (20)] -, -SO m -, -NR (20) -, -NR (20) -CO-, -NR (20) -CO-NH-, -NR (20) -CO-NH-SO 2 -
  • R (19) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms
  • R (20) is hydrogen or methyl
  • B is a phenylene or naphthylene radical
  • R (12) and R (13) independently of one another hydrogen, methyl, F, Cl, Br, J, CF 3 or -SO w -R (14);
  • R (15) and R (16) independently of one another are hydrogen or alkyl having 1, 2,
  • R (21) is hydrogen or methyl; m zero, 1 or 2; and the other substituents R (1) and R (2) and R (3) independently of one another are hydrogen, F, Cl, Br, J, -CN, - (C r C 8 ) -alkyl, - (C 2 - C 8 ) -alkenyl, -NR (35) R (36) or R (17) -C 8 H 2g -Z h -; g zero, 1, 2, 3 or 4; h zero or 1; R (35) and R (36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms; or R (35) and R (36) together 4-7 methylene groups, of which one CH 2 group can be replaced by oxygen, -S-, -NH-, -NCH 3 or -N-benzyl; Z -O-, -CO-, -SO v -, -NR (18) -, -NR (18) -CO-, -NR (18) -CO
  • R (18) is hydrogen or methyl; v zero, 1 or 2; R (17) is hydrogen, cycloalkyl having 3, 5 or 6 carbon atoms or C k F 2k + 1 -; k 1, 2 or 3, or R (17) pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is unsubstituted or substituted with 1-4 substituents selected from the group consisting of F, Cl , Br, I, -CN, (C 2 -C 8 ) alkanoyl, (C 2 -C 8 ) alkoxycarbonyl, formyl, carboxy, -CF 3 , methyl and methoxy; or R (17) - (C 3 -C 8 ) -cycloalkyl or phenyl which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F and Cl, -CF 3 , methyl, hydroxy, methoxy, - NR (37) R (38), CH
  • R (4) and R (5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR (32), -NR (33) R (34) or -C r F 2r + 1 ; R (32), R (33) and R (34) independently of one another hydrogen or alkyl having 1, 2 or 3 carbon atoms; r 1, 2, 3 or 4;
  • Rd) and R (2) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms.
  • O-alkyl with 1, 2, 3 or 4 C-atoms, OC ( O) -alkyl with 1, 2, 3 or 4 C-atoms or C m H 2m -NR (12) R ⁇ 13);
  • R (12) and R (13) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; m nuill, 2, 3 or 4;
  • R (1 1) C r C 4 alkyl, C r C 4 alkynyl, aryl, substituted aryl, NH 2 , NH-C r C 4 alkyl, N- (C r C 4 alkyl) 2 , SO 3 H, SO 2 -alkyl, SO 2 - alkylaryl, SO 2 -N- (alkyl) 2, SO 2 -N (alkyl) (alkylaryl);
  • R (7), R (8), R (9) and R (10) independently of one another are hydrogen, alkyl, cycloalkyl, aryl, alkylaryl; or
  • R (8) and R (9) together form part of a 5, 6 or 7-membered heterocyclic ring
  • R (1), R (2) and R (3) independently of one another are -Y- [4-R (8) -phenyl], -Y- [3-R (8) -phenyl] or -Y- [2- R (8) -phenyl], where the phenyl is in each case unsubstituted or substituted with 1-2 substituents from the group consisting of F, Cl, -CF 3 , methyl, hydroxy, methoxy and -NR (96) R ( 97); R (96) and R (97) independently of one another are hydrogen or -CH 3 ; Y is a bond, CH 2 , oxygen, -S- or -NR (9);
  • R ⁇ 9) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
  • R (8) SO a [NR (98)] b NR (99) R (10); a 1 or 2; b 0 or 1; a + b 2;
  • R (98), R (99) and R (10) independently of one another are hydrogen, - (C r C 8 ) -alkyl, benzyl,
  • R (1 1), R (12), R (13), R (37), R (38), R (43) and R (44) independently of one another are hydrogen, - (C r C 8 ) -alkyl or benzyl : R (39), R (40), R (41) and R (42) independently of one another are hydrogen, - (C r C 8 ) -alkyl or - ⁇ C 0 -C 3 ) -alkylene-phenyl, the phenyl not is substituted or substituted with 1-3 substituents selected from the group consisting of F, CI, -CF 3 , methyl and methoxy; or R (99) and R (10) together 4-6 methylene groups, of which one CH 2 group can be replaced by oxygen, -S-, -NH-, -N-CH 3 or -N-benzyl; or
  • R (8) SO a [NR (98)] b NR (95) -C [ NR (94)] - NR (93)
  • R (92); R (92), R (93), R (94) and R (95) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or Rd), R (2) and R ⁇ 3) independently of one another pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is unsubstituted or substituted with 1-4 substituents selected from the group consisting of F, Cl, Br, I, -CN, (C 2 -C 8 ) alkanoyl, (C 2 -C 8 ) alkoxycarbonyl, formyl, carboxy, -CF 3 , methyl, methoxy; or Rd), R (2) and R (3) independently of one another are hydrogen, - (C r C 8 ) -alkyl, - (C 2 -C 8 ) -alkenyl or
  • R (18) is hydrogen or - (C r C 4 ) -alkyl;
  • R (21) and R (22) independently of one another are hydrogen, - (C r C 8 ) -alkyl, - (C r C 8 ) -alkanoyl, - (C., - C 8 ) -alkoxycarbonyl, benzyl, benzyloxycarbonyl; or
  • R (23), R (24) independently of one another
  • R (26) and R (27) independently of one another are defined as R (25) or hydrogen or (C r C 4 ) -alkyl, or Rd), R (2) and R (3) independently of one another (C ⁇ CgJ-heteroaryl -N-oxide which is linked via C or N and which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; or R (1), R (2) and R (3) independently of one another -SR ⁇ 28), -OR (28), -NR (28) R (29) or
  • R (28) -C 8 H 2g - (C 1 -C 9 ) heteroaryl-N-oxide which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , Methoxy, hydroxy, amino, methylamino and dimethylamino; g zero, 1 or 2; R (29), R (30) independently defined as R (28), hydrogen or (C r C 4 ) alkyl; or Rd), R (2) and R (3) independently of one another hydrogen, F, Cl, Br, I, -C N, T- (CH 2 ) h -
  • T is a bond, oxygen, -S- or -NR (47);
  • I zero, 1 or 2; h zero, 1 or 2; i 1, 2, 3, 4, 5 or 6;
  • R (31), R (32), R (34> and R (45) independently of one another - (C 1 -C 8 ) alkyl, - (C 3 -C 6 ) alkenyl,
  • R ⁇ 47 hydrogen or alkyl having 1, 2 or 3 carbon atoms
  • R (33) and R (46) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or R (32) and R (33) and R (45) and R (46) together have 5 or 6 methylene groups, one of which is a CH 2 group by oxygen, -S-, -NH-, -NCH 3 or -N- Benzyl can be replaced; or Rd), R (2) and R (3) independently of one another R (51) -AGD-;
  • R (51) is a basic protonatable residue, i.e. an amino group
  • R (52), R (53), R (54) and R (55) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4
  • R (56) is hydrogen or methyl; or R (51) is a basic heteroaromatic ring system with 1-9 C atoms;
  • A is a group C ⁇ H 2 ⁇ ; e zero, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; where in the group C ⁇ H 2e a carbon atom is defined by one of the groupings -O-, -CO-, -CH (OR (57)] -, -SO r -, -NR (57) -, -NR (57 ) - CO-, -NR (57) -CO-NH-, -NR (57) -CO-NH-SO 2 - or -NR (57) -SO 2 - can be replaced; r zero, 1 or 2;
  • G is a phenylene radical
  • R (58) and R (59) independently of one another hydrogen, methyl, methoxy, F, Cl, Br, J, CF 3 or -SO S -R (60);
  • R (61) and R (62) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; D -C v H 2v -E w -; v zero, 1, 2, 3 or 4;
  • Group can be replaced by oxygen, -S-, SO 2 , -NH-, -NCH 3 or -N-benzyl;
  • R (4) and R (5) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR (69), -NR (70) R (71) or -C 2 F 2z + 1 ;
  • R (69), R (70) and R (71) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms.
  • R (6) and R (7) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; X is oxygen or NR (72);
  • R (72) is hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; and their pharmaceutically acceptable salts; (HOE 95 / F 1 1 5 - EP 744 397, NZ 286 622) al) alkenylcarboxylic acid guanidides of formula I bearing fluorophenyl groups
  • R (6) is hydrogen, (C r C 8 ) -alkyl, (C 3 -C 8 ) -cycloalkyl or phenyl, the phenyl group not being substituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (9) R (10); R (9) and RdO)
  • R (7) is independently defined as R (6); Rd), R (2), R (3), R ⁇ 4) and R (5) independently of one another are hydrogen or F; however, at least one of the radicals R (1), R (2), R (3), R (4) and R (5) must be fluorine; and their pharmaceutically acceptable salts;
  • X CR (16) R (17), O, S or NR (18); R (16), R (17) and R (18) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; a zero or 1;
  • alkylene with 1, 2, 3, 4, 5, 6, 7 or 8 C atoms
  • alkylene T with 1, 2, 3, 4, 5, 6, 7 or 8 C atoms in the alkylene group
  • T, T-alkylene with 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms in the alkylene group
  • T NR (20) O, S or phenylene, the phenylene being unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and
  • R (20), R (21) and R ⁇ 22) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; b zero or 1;
  • R (24) and R (25) independently of one another are hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; or R (24) and R (25) together 4 or 5 methylene groups, of which one CH 2 group can be replaced by oxygen, S, NH, N-CH3 or N-benzyl; wherein the N-containing heterocycles are N- or C-bridged and are not substituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl, methoxy and NR (27) R (28); R (23), R (27) and R (28) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; and the respective other substituents R (1)
  • R (12); R (11) and R (12) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atoms; R (6) and R (7) independently of one another hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, cycloalkyl having 3, 4, 5, 6, 7 or 8 C atoms, or phenyl which is unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of F, Cl, CF 3 , Methyl, methoxy and NR
  • one of the radicals R (1), R (2), R (3) and R (4) -CO-N C (NH 2 ) 2 ; and the other radicals R (1), R (2), R (3) and R (4):
  • Rd hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, -OR (32), -NR (33) R (34) or CF 3 ;
  • R (32), R (33) and R (34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
  • R (2) and R (4) independently of one another pyrrol-1-yl, pyrrol-2-yl or pyrrol-3-yl, which is unsubstituted or substituted with 1-4 substituents selected from the group consisting of F, Cl , Br, I, -CN, (C 2 -C 8 ) alkanoyl, (C 2 -C 8 ) alkoxycarbonyl, formyl, carboxy, -CF 3 , methyl, methoxy; or R (2) and R (4) independently of one another R (22) -SO 2 -, R (23) R (24) N-CO-, R (28) -CO- or
  • R (22) and R (28) independently of one another are methyl or -CF 3 ;
  • R (35) and R (36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms; or R ⁇ 35) and R (36) together 4-7 methylene groups, of which one CH 2 group can be replaced by oxygen, -S-, -NH-, -NCH 3 or -N-benzyl;
  • R (25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF. 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; or R (25) - (C r C 9 ) heteroaryl, which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 # CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino ; R (26) and R (27) independently of one another are defined as R (25) or hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; R (5) alkyl with 1, 2, 3 or 4 carbon atoms, F, Cl, Br, I, X- (CH 2 ) y -CF 3 or phenyl, which is unsubstituted
  • R (25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF. 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino; or R (25 - (C r C 9 ) heteroaryl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino;
  • R (26) and R (27) independently of one another are defined as R (25) or hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; R (4) CF 3 , alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, alkenyl with 2, 3, 4, 5, 6, 7 or 8 carbon atoms, - (C 3 -C
  • R (32), R (33) and R (34) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; the other radicals R (2) and R (4) independently of one another hydrogen, F, Cl, Br, I, OH, -CN, CF 3 ,
  • -CO-N C (NH 2 ) 2 , alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, alkenyl having 2, 3, 4, 5, 6, 7 or 8 C- Atoms or - (CH 2 ) m R (14); m zero, 1 or 2;
  • R (23), R (24), R (29) and R (30) independently of one another are hydrogen or methyl; or the respective other radicals
  • R (35) and R (36) independently of one another are hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms; or
  • R (25) is hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl which is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF.
  • R (25) - (C r C g ) heteroaryl which is unsubstituted or substituted with 1-3 substituents selected from the group consisting of F, Cl, CF 3 , CH 3 , methoxy, hydroxy, amino, methylamino and dimethylamino
  • R (26) and R (27) independently of one another are defined as R (25) or hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms; one of the radicals R (6), R (7), R (8), R ⁇ 9) and R (10)
  • -CO-N C (NH 2 ) 2 ;
  • the other radicals R (6) and R (10) independently of one another are hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, F, Cl, -OR (132), -NR (133) R (134) or CF 3 ;
  • R (132), R (133) and R (134) independently of one another are hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms;
  • R (135) and R (I 36) together have 4-7 methylene groups, of which one CH 2 group can be replaced by oxygen, -S-, -NH-, -NCH 3 or -N-benzyl; the other R (8)
  • R (126) and R (127) independently of one another are defined as R (125) or are hydrogen or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms;
  • a absent, -NR (1 1) -CO-, -NR (12) -CO-NR (13) -, -NR (17) -CO-NR (18) -SO 2 -, - NR (19) - SO 2 -, -SO 2 -NR (19) -SO 2 -NR (19) -CO 2 -NR (19) -CO 2 -NR (19) -CO-, -O-CO-NR (19) -SO 2 - or -CR (20) CR (21) -; R (1 1), R (12), R (13), R (17), R (18), R (19), R (20) and
  • R (41) and R ⁇ 42) independently of one another hydrogen, alkyl with 1, 2, 3 or 4 carbon atoms, perfluoroalkyl with 1, 2, 3 or 4 carbon atoms, or R (41) and R (42) together 4 or 5 methylene groups, one of which is CH 2 - group can be replaced by oxygen, S, NH, N-CH 3 or N-benzyl; and the other substituents R (1), R (2) and R (3) independently of one another are H, F, Ci, Br, I, CN, -O na -C ma H 2ma + 1 or -
  • R (10) cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl, the phenyl not being substituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3 , methyl and methoxy;
  • R (4) and R (5) independently of one another are hydrogen, F, Cl, Br, I, CN, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, perfluoroalkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms, cycloalkyl with 3, 4, 5, 6, 7 or 8 carbon atoms or phenyl which is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of from F, Cl, CF 3 , methyl, methoxy and NR (14)
  • R (14) and R (15) independently of one another are H, alkyl having 1, 2, 3 or 4 carbon atoms or perfluoroalkyl having 1, 2, 3 or 4 carbon atom
  • NHE inhibitors are therefore suitable, for example, for the treatment of ischemically induced arrhythmias, different forms of angina pectoris, for heart transplants, in cardiac surgery and for angioplasty surgical interventions.
  • Other described indications for NHE inhibitors are stroke and cerebral edema, shock and proliferation-related diseases such as atherosclerosis, late diabetic damage, fibrotic diseases and organ hypertrophy.
  • NHE inhibitors can stimulate respiration by increasing the chemosensitivity of the respiratory chemoreceptors.
  • These chemoreceptors are largely responsible for maintaining orderly breathing. They are activated by hypoxia, a drop in pH and an increase in CO2 (hypercapnia) in the body and lead to an adjustment of the minute ventilation. Breathing is particularly susceptible to disruption during sleep and is highly dependent on the activity of the chemoreceptors.
  • An improvement in respiratory drive through stimulation of the chemoreceptors with substances that inhibit sodium-proton exchange leads to an improvement in breathing in the following clinical conditions and diseases: impaired central respiratory drive (e.g. central sleep apnea, sudden child death, postoperative hypoxia), muscular-related breathing disorders, breathing disorders after long-term ventilation, breathing disorders when adapting to high mountains, obstructive and mixed form of sleep apneas, acute and chronic lung diseases with hypoxia and hypercapnia.
  • impaired central respiratory drive e.g. central sleep apnea, sudden child death, postoperative hypoxia
  • muscular-related breathing disorders e.g. central sleep apnea, sudden child death, postoperative hypoxia
  • muscular-related breathing disorders e.g. central sleep apnea, sudden child death, postoperative hypoxia
  • muscular-related breathing disorders e.g. central sleep apnea, sudden child death, postoperative hypoxia
  • muscular-related breathing disorders e.g. central sleep ap
  • the compounds mentioned are therefore advantageously used individually or in groups for the manufacture of a medicament for the treatment of disturbed respiratory drive; for the manufacture of a medicament for the treatment of muscular breathing disorders; for the manufacture of a medicament for the treatment of breathing disorders after long-term ventilation; for the manufacture of a medicament for the treatment of breathing disorders when adapting to high mountains; for the manufacture of a medicament for the treatment of obstructive, central and mixed forms of sleep apneas; for the manufacture of a medicament for the treatment of acute and chronic lung diseases with hypoxia and hypercapnia; especially for the manufacture of a medicament for the treatment of the conditions mentioned in combinations with an inhibitor of carbonic anhydratase, preferably with acetazolamide.
  • a combination of an NHE inhibitor with a carbonic anhydrase inhibitor e.g. acetazolamide
  • a carbonic anhydrase inhibitor e.g. acetazolamide
  • sodium proton exchange inhibitors is claimed as a novel medicine to improve breathing, respiratory stimulants, and the combination of sodium proton exchange inhibitors with carbonic anhydrase inhibitors.

Abstract

Les principes actifs identifiés comme étant des inhibiteurs de l'échangeur Na+/H+ (NHE) sont particulièrement indiqués pour préparer un médicament stimulant la respiration. Ces principes actifs sont particulièrement bien adaptés au traitement des apnées du sommeil ou d'autres troubles de la respiration.
EP96943956A 1995-12-27 1996-12-13 UTILISATION D'INHIBITEURS DE L'ECHANGEUR CELLULAIRE Na?+ /H?+ (NHE) POUR PREPARER UN MEDICAMENT STIMULANT LA RESPIRATION Withdrawn EP0869779A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19548812 1995-12-27
DE19548812A DE19548812A1 (de) 1995-12-27 1995-12-27 Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
PCT/EP1996/005614 WO1997024113A1 (fr) 1995-12-27 1996-12-13 UTILISATION D'INHIBITEURS DE L'ECHANGEUR CELLULAIRE Na+/H+ (NHE) POUR PREPARER UN MEDICAMENT STIMULANT LA RESPIRATION

Publications (1)

Publication Number Publication Date
EP0869779A1 true EP0869779A1 (fr) 1998-10-14

Family

ID=7781474

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96943956A Withdrawn EP0869779A1 (fr) 1995-12-27 1996-12-13 UTILISATION D'INHIBITEURS DE L'ECHANGEUR CELLULAIRE Na?+ /H?+ (NHE) POUR PREPARER UN MEDICAMENT STIMULANT LA RESPIRATION

Country Status (16)

Country Link
EP (1) EP0869779A1 (fr)
KR (1) KR19990076802A (fr)
CN (1) CN1207676A (fr)
AU (1) AU717247B2 (fr)
BR (1) BR9612287A (fr)
CA (1) CA2241531A1 (fr)
CZ (1) CZ202198DA3 (fr)
DE (1) DE19548812A1 (fr)
HU (1) HUP9900807A3 (fr)
IL (1) IL125114A0 (fr)
MX (1) MX9805141A (fr)
NO (1) NO982989L (fr)
PL (1) PL327693A1 (fr)
SK (1) SK88398A3 (fr)
TR (1) TR199801235T2 (fr)
WO (1) WO1997024113A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
DE19945302A1 (de) * 1999-09-22 2001-03-29 Merck Patent Gmbh Biphenylderivate als NHE-3-Inhibitoren
DE10060292A1 (de) 2000-12-05 2002-06-20 Aventis Pharma Gmbh Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
AU2009334511C1 (en) 2008-12-31 2016-08-18 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR102138390B1 (ko) 2012-08-21 2020-07-27 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 ｎｈｅ-매개된 역수송 저해를 위한 화합물 및 방법
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2014250956B2 (en) 2013-04-12 2019-04-04 Ardelyx, Inc. NHE3-binding compounds and methods for inhibiting phosphate transport
ES2701498T3 (es) 2014-07-25 2019-02-22 Taisho Pharmaceutical Co Ltd Compuesto de feniltetrahidroisoquinolina sustituido con heteroarilo
EP3565808A1 (fr) 2017-01-09 2019-11-13 Ardelyx, Inc. Composés utiles pour le traitement de troubles du tractus digestif
CA3049679A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibiteurs d'antiport a mediation par nhe
IL272443B2 (en) 2017-08-04 2024-02-01 Ardelyx Inc History of glycyrrhizinic acid for the treatment of excess potassium in the blood
AU2020218255A1 (en) 2019-02-07 2021-09-09 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0639573A1 (fr) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
DE4337609A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4415873A1 (de) * 1994-05-05 1995-11-09 Hoechst Ag Substituierte bizyklische Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9724113A1 *

Also Published As

Publication number Publication date
IL125114A0 (en) 1999-01-26
BR9612287A (pt) 2005-05-24
AU717247B2 (en) 2000-03-23
NO982989L (no) 1998-08-06
HUP9900807A3 (en) 2000-11-28
SK88398A3 (en) 1999-03-12
PL327693A1 (en) 1998-12-21
AU1372097A (en) 1997-07-28
TR199801235T2 (xx) 1998-10-21
WO1997024113A1 (fr) 1997-07-10
NO982989D0 (no) 1998-06-26
KR19990076802A (ko) 1999-10-15
MX9805141A (es) 1998-10-31
CA2241531A1 (fr) 1997-07-10
CZ202198DA3 (cs) 1998-11-11
CN1207676A (zh) 1999-02-10
HUP9900807A2 (hu) 1999-07-28
DE19548812A1 (de) 1997-07-03

Similar Documents

Publication Publication Date Title
WO1997046226A2 (fr) UTILISATION D'INHIBITEURS DE L'ECHANGEUR CELLULAIRE Na+/H+ (NHE) POUR PREPARER UN MEDICAMENT PERMETTANT DE NORMALISER LES LIPIDES SERIQUES
WO1997024113A1 (fr) UTILISATION D'INHIBITEURS DE L'ECHANGEUR CELLULAIRE Na+/H+ (NHE) POUR PREPARER UN MEDICAMENT STIMULANT LA RESPIRATION
EP0937464B1 (fr) Préparation pharmaceutique sous forme d'association contenant un inhibiteur de l'échange sodium-hydrogène et un médicament pour le traitement de maladies cardiovasculaires
CH650926A5 (de) Antiparkinson-mittel.
DE19859727A1 (de) Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
AU738599B2 (en) Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa
DE19738604A1 (de) Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verminderung der Giftigkeit cardiotoxischer Stoffe
EP0909559A2 (fr) Utilisation d'inhibiteurs de l'échange sodium-hydrogène pour la fabrication d'un médicament pour le traitement ou la prophylaxie de maladies du système nerveux central
DE19750498A1 (de) Die Verwendung eines Inhibitors des Na+/H+-Austauschers zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von Erkrankungen des Zentralnervensystems
DE19742096A1 (de) Die Verwendung eines Inhibitors des Na·+·/H·+·-Austauschers zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von Erkrankungen des Zentralnervensystems
DE19712636A1 (de) Verwendung von Inhibitoren des zellulären Na+/H+Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
US20040122096A1 (en) Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids
Graham Structure and activity in a series of 2-halogenoalkylamines
JP2000500774A (ja) 呼吸刺激のための医薬製造での細胞内Ｎａ▲上＋▼／Ｈ▲上＋▼交換物質（ＮＨＥ）の抑制剤の使用
MXPA98006923A (en) Pharmaceutical combined preparation based on an inhibitor of the exchanger between sodium and hydrogen and of a medicine intended for the treatment of cardio-circulatory diseases
DE1493941B (de) 1 unterstrichen 1 (4 Nitrophenyl) 2 lsopropylaminoathanol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 980727

17Q First examination report despatched

Effective date: 20010712

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20011102